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Peripheral neuropathies can be classified into two categories, demyelinating or 
axonal neuropathy. Demyelinating neuropathies are characterized by damaged myelin but 
intact axons. Recent evidence suggests that the leucine zipper transcription factor c-jun is 
at the center of driving demyelination. c-Jun is required for Schwann cells (SCs) to 
dedifferentiate after injury, and up-regulation of c-jun has been reported in human 
neuropathies. It remains to be tested whether c-jun would be a valid target for treating 
demyelinating neuropathies. Previously, our published work has shown that modulating 
the expression of heat shock protein 70 (Hsp70) using a novel small molecule drug called 
KU-32 attenuated the expression of c-jun and the extent of demyelination in SC-dorsal 
root ganglia (DRG) co-cultures in an Hsp70 dependent manner.  
To extend these data, this work examined the in vivo effects of modulating 
molecular chaperones using the next generation novologue KU-596 in two mouse models 
of demyelinating neuropathies. MPZ-Raf mice are a conditional transgenic mouse line 
that exhibits a demyelinating neuropathy due to the SC-specific induction of mitogen-
activated protein kinase (MAPK) and c-jun induction after tamoxifen (TMX) injections 
in adult mice. Five days of TMX treatment induced a severe motor deficits starting from 
day 8 and treating the MPZ-Raf mice with 20 mg/kg of KU-596 every other day reduced 
c-jun levels in the sciatic nerves. The decrease in c-jun correlated with an improvement in 
the myelination status of the nerves and motor function. In line with previous findings, 
the effects of KU-596 were Hsp70-dependent, as MPZ-RAF × Hsp70 knockout (KO) 
mice did not show improvement following drug treatment. This study provides proof of 
principal that modulating molecular chaperones would be beneficial in treating 
demyelinating neuropathies. However, as this model is less relevant to an actual disease, 
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we complemented our study using a model of human X-linked Charcot-Marie-Tooth 
disease (CMT1X).  
CMT1X is caused by the mutation of gap junction beta 1 gene (GJB1) that 
encodes the gap junction protein connexin 32 (Cx32). Recent evidence suggests an 
elevated c-jun expression is associated with the disease. Since c-jun could promote 
demyelination, targeting c-jun using KU-596 could provide a potential therapeutic 
strategy to treat CMT1X. The pathology of Cx32 deficient (Cx32def) mice occurs in two 
stages where young mice develop a pre-demyelinating axonopathy, which progresses to a 
more severe demyelinating neuropathy in older mice. We show that in young mice that 
exhibit a pre-demyelinating axonopathy, one-month of KU-596 treatment decreased c-jun 
expression and improved motor nerve conduction velocity (MNCV) and compound 
muscle action potential (CMAP). In older Cx32def mice that developed a demyelinating 
neuropathy, 3 months of KU-596 treatment decreased c-jun expression and improved grip 
strength, MNCV and CMAP. Hsp70 is required for drug efficacy as neither young nor 
old Cx32def × Hsp70 KO mice showed improvement following KU-596 treatment. 
Collectively, our data indicates that modulating molecular chaperones is beneficial in 
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Chapter 1. Introduction 
1.1. Overview of Peripheral Myelination 
Myelin insulates the axons and enables the fast conduction of electrical signals along 
the length of the nerve fiber. Schwann cells (SCs) supply the myelin for the peripheral 
nervous system (PNS) and were first described by Theodor Schwann as the ensheathing 
structure around peripheral axons. SCs originate from neural crest cells, which segregate 
from the neural folds during neurulation and migrate either laterally and ventrally to form 
various neurons (Jessen & Mirsky 2005). SCs mature over three transitional periods 
(Figure 1.1.1.1) with Schwann cell precursors (SCPs) first differentiating from neural 
crest cells around embryonic day 12-13 (E12-13). Surprisingly, SCPs are not required for 
nerves to reach their targets (Grim et al 1992, Morris et al 1999) but are required for 
nerve fasciculation (Birchmeier 2009). SCPs provide trophic support for sensory and 
motor neurons and give rise to endoneurial fibroblasts, melanoblasts, and 
parasympathetic neurons in addition to SCs (Dyachuk et al 2014, Espinosa-Medina et al 
2014, Jessen & Mirsky 2005, Joseph et al 2004, Kaucka & Adameyko 2014, Nitzan et al 
2013).  
At E15-16, SCPs transition into immature SCs. A series of lineage-specific markers 
distinguishes SCPs from immature SCs. For example, SCPs express the low affinity p75 
neurotrophin receptor and growth-associated protein (GAP)-43, while immature SCs 
mainly express S100 and neuronal cellular adhesion molecules (NCAMs) (Kubu et al 
2002, White et al 2001). Immature SCs then differentiate into either myelinating or non-
myelinating SCs depending on the axons they ensheath. In particular, axons with a 
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diameter larger than 1µm are typically myelinated (Corfas et al 2004, Sherman & Brophy 
2005). Radial sorting enables immature SCs to form 1:1 relationships with axons and 
initiates a pro-myelinating stage, during which promyelinating proteins such as myelin-
associated glycoprotein (MAG), protein zero (P0), and octamer binding transcription 
factor (Oct-6) are expressed (Ogata et al 2006).  The myelination process initiates at birth 
and is characterized by the downregulation of Oct-6 and increased expression of Krox-
20, a key transcription factor that functions as a positive regulator of myelination (Jaegle 
& Meijer 1998).  
Myelinated SCs maintain a striking plasticity that enables them to switch off 
myelination, re-enter the cell cycle, and re-adopt a phenotype that is similar to immature 
SCs. Dedifferentiation of SCs often occurs in injured nerves, when they lose contact with 
the axons. Demyelinated axons are also a common feature in human neuropathies, such 
as Charcot-Marie-Tooth disease (CMT) and Refsun disease, even in the absence of direct 
nerve injury (Scherer & Wrabetz 2008). Dedifferentiated SCs can re-differentiate and 
remyelinate the axons under appropriate conditions. Since SC differentiation and 
dedifferentiation are tightly regulated by the interplay between different intracellular 
signals, elucidating the underpinning molecular events is the key to help understand SC 
biology and devise treatments for demyelinating neuropathies. 
1.1.1. Positive regulators of myelination 
Several transcription factors, including Krox-20, Oct-6, Brn-2, Sox-10 and NF-κB 
have been identified to be pro-myelinating. Krox-20 is a zinc finger transcription factor 
and is necessary for driving SC myelination as well as the formation and maintenance of 
the myelin sheath (Decker et al 2006). Specifically, Krox-20 activates myelin genes, 
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suppresses the expression of negative regulators of myelination (see below), helps SCs 
exit the cell cycle and blocks proliferation. Consistent with its important role in 
myelination, Krox-20 null mice fail to express genes necessary for myelin differentiation 
even after the SCs reach the promyelinating stage (Parkinson et al 2003). Enforced Krox-
20 expression is sufficient to induce expression of myelin gene P0 and periaxin in 
dedifferentiated SCs (Nagarajan et al 2001).  
Figure 1.1.1.1: Schematic illustraion of SC lineage and regulators of SC myelination.  
SC maturation is a three-phase process, including migration of neural crest cells, differentiation 
into immature SCs, and maturation into myelinating or non-myelinating SCs. Large fibers are 
ensheathed with myelinating SCs, and small caliber fibers form Remak bundles with non-
myelinating SCs. Red arrows indicate SC dedifferentiation upon injury or in pathological settings. 
Factors regulating each transition process are listed above. Factors in bold are evidenced with 





1.1.2. Negative regulators of myelination 
Negative regulators, such as c-jun, Notch, Sox-2, and Id2, inhibit myelination and 
can dedifferentiate SCs back into the immature phenotype in injured nerves. Since this 
transformation of SCs creates an environment that is preferable for axonal survival and 
regeneration, negative regulators are crucial for nerve recovery after injury. 
Mechanistically, Parkinson et al. suggested that c-jun and Notch may directly antagonize 
the myelin-promoting transcription factor, Krox-20 (Parkinson et al 2008). Therefore, 
negative and positive regulators maintain a dynamic balance between myelination and 
demyelination in peripheral nerves by functionally complementing each other. However, 
this balance may be disturbed and abnormal induction of negative signaling may cause 
pathological demyelination in a variety of human pathologies, including CMT. Hence, a 
clear elucidation of the molecular and cellular functions of the negative regulators in SCs 
will be particularly instructive for developing effective therapies for treating some 
myelin-related diseases.  
 c-Jun 1.1.2.1.
c-Jun, together with JunB and JunD, belongs to the mammalian Jun protein family 
and is a major component of the AP-1 transcription factor complex (Mechta-Grigoriou et 
al 2001). Although most of the activities of c-jun depend on its N-terminal 
phosphorylation by Jun-NH2-terminal kinase (JNK), c-jun-mediated myelin gene 
regulation appears to be independent of this pathway. In support of this, expression of a 
mutant c-jun that is resistant to JNK phosphorylation retained its inhibitory effects on 
myelin gene expression compared to wild-type c-jun (Parkinson et al 2008). c-Jun is 
highly expressed in immature SCs and is down regulated as SCs begin to myelinate and 
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Krox-20 expression increases. Overexpression of Krox-20 suppressed basal c-jun levels 
in cultured SCs in vitro (Parkinson et al 2004) and consistent with this observation, c-jun 
levels remained high in the postnatal nerves of Krox-20 null mice but were suppressed in 
wild type nerves (Mirsky et al 2008). Wild-type (WT) and mutant c-jun (resistant to JNK 
phosphorylation) also antagonized the expression of Krox-20 induced by another pro-
myelinating molecule, dibutryl cAMP (db-cAMP) (Parkinson et al 2008).  
The above data support that Krox-20 can block c-jun expression but c-jun also has 
a cross-inhibitory relationship with Krox-20. c-Jun inhibits myelin genes during 
development and in c-jun-null SCs, Krox-20-induced myelin gene expression was shown 
to be elevated. However, inhibition of c-jun pathway alone was not sufficient to induce 
differentiation in myelinated nerves (Parkinson et al 2008). Modest overexpression of c-
jun during development delays myelination, and higher expression of c-jun inhibits 
myelination (Fazal et al 2017).  
During nerve injury, loss of axonal contact causes myelinated SCs to arrest 
myelination and revert to a phenotype similar to the immature stage. This process is 
characterized by cessation of myelin gene expression and reactivation of genes 
characteristic of immature SCs, such as downregulation of Krox-20 levels and 
upregulation of c-jun levels. To characterize the role of c-jun in this process, researchers 
generated mice containing a SC specific, conditional knockout of c-jun. In these mice, 
there was a significant delay in injury-induced myelin sheath degradation and loss of 
myelin mRNA and protein expression. Particularly, while Krox-20 expression 
disappeared in WT mice 24h after the removal of axon contact, it remained detectable 2d 
after loss of axon contact in the c-jun null mice. Contrarily, c-jun expression is highly 
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upregulated following nerve cut in WT mice but remained low in the mutant mice with 
the conditional deletion. These results indicate that c-jun is necessary for SCs to re-adopt 
the immature phenotype (Parkinson et al 2008).  
The essential role of c-jun during regeneration after injury is also well illustrated 
using the slow Wallerian degeneration protein (WLDs) mice (Coleman & Freeman 2010). 
In WLDs mice, SCs remain differentiated, were unable to induce c-jun expression and the 
transected myelinated nerves degenerated much slower than wild-type nerve (Jessen & 
Mirsky 2008). However, this impaired nerve regeneration in WLDs mice was rescued by 
forcing c-jun expression (Arthur-Farraj et al 2012). Further investigation by Fontana and 
colleagues suggested that two genes that are directly targeted by c-jun, glial-derived 
neurotrophic factor (GDNF) and artemin, might mediate c-jun-dependent nerve 
regeneration, since exogenous delivery of GDNF and artemin to selectively deleted c-jun 
in SCs mice partially rescued axonal regeneration (Fontana et al 2012a). Therefore, it 
seems clear that c-jun negatively regulates myelination, and more importantly, c-jun 
drives the dedifferentiation program and guides axon regeneration after injury. 
 Notch 1.1.2.2.
Notch is a Type I transmembrane receptor and functions as another important 
negative regulator of SC myelination. The Notch receptor family includes four members 
(Notch 1-4) that can be activated by five endogenously expressed ligands: Jagged-1, -2 
and Delta-1, -3, -4. All four Notch receptors share a similar structure: an extracellular 
domain consisting of 36 epidermal growth-like repeats and an intracellular domain 
containing various sequences that are crucial for functions such as receptor 
transactivation and nuclear localization (Aparicio et al 2013, Deregowski et al 2006, 
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Jurynczyk & Selmaj 2010, Oberg et al 2001). Notch receptors form heterodimers on the 
plasma membrane and can be activated by two successive cleavages following ligand 
binding. Notch is first cleaved by a disintegrin and metalloproteinase (ADAM) at site 2, 
creating a membrane tethered intermediate, which is then further cleaved by γ-secretase, 
releasing the Notch intracellular domain (NICD). The NICD then translocates to the 
nucleus, where it associates with the DNA binding protein (recombination signal-binding 
protein Jκ (RBPJ) in mammals) and other transcriptional coactivators to bind and activate 
target genes (Kopan & Ilagan 2009). Notch signaling promotes SC development and 
aberrant Notch signaling could transform rat SCs (Li et al 2004).  
In the context of negatively regulating myelination, Notch appears to be 
independent of RBPJ, since the NICD suppressed cAMP-induced expression of myelin 
proteins and Krox-20 in the absence of RBPJ (Woodhoo et al 2009). Interestingly, Notch 
appears to be able to induce myelin loss even in uncut nerves in vitro and in vivo. In these 
studies, adenovirus overexpressing Notch (Ad-NICD) induced myelin damage in 
myelinated neuron-SCs co-cultures; the same result was obtained when injecting Ad-
NICD into intact nerves (Woodhoo et al 2009). Notch also functions in nerve repair. The 
addition of recombinant Jagged-1 (ligand for Notch 1) promoted nerve regeneration and 
recovery after nerve injury (Boerboom et al 2017, Wang et al 2015). This indicates that a 
tight control of Notch signaling is essential for maintaining myelin integrity.  
Similar to c-jun, the NICD can be suppressed by Krox-20 expression in vivo and in 
vitro. For example, Krox-20 inhibits expression of the NICD in myelinating SCs. 
Conversely, NICD levels remain high in Krox-20-/- animals (Woodhoo et al 2009).  All of 
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these findings indicate that Notch signaling is a potentially powerful negative regulator of 
myelination, yet it may play a minor role in comparison with c-jun. 
 Mitogen-activated protein kinases (MAPKs)  1.1.2.3.
Apart from the observation of c-jun and Notch described above, demyelination also 
requires the engagement of intracellular signaling pathways. The Ras/Raf/ERK pathway 
was demonstrated both in vitro (Harrisingh et al 2004) and in vivo (Napoli et al 2012b) to 
negatively regulate myelination. Raf activation blocks SC differentiation and induces 
dedifferentiation even in uninjured nerves (Harrisingh et al 2004). Using specially 
engineered mice with a tamoxifeninducible, Raf-kinase/estrogen receptor fusion protein 
(RafTR) expressed specifically in myelinating SCs, tamoxifen-induced Raf activation 
downregulated myelin protein expression and induced demyelination in sciatic nerves. c-
Jun and Notch ligand expression were strongly upregulated by Raf activation, placing 
both c-jun and Notch downstream of ERK signaling (Napoli et al 2012b). Conversely, 
another group demonstrated that Rac-MKK7-JNK pathway, but not the Raf-ERK 
pathway, functions as a negative regulator of myelination. They found that inhibition of 
Rac could suppress c-jun induction in injured nerves, but inhibition of ERK could not. 
Microarray analysis also showed that the expression of regeneration-associated genes is 
dependent on Rac but not ERK (Shin et al 2013). It is possible that Rac and Raf function 
as distinct pathways and the latter does not act through c-jun to regulate myelination.  
p38 MAPK has been shown to play a dual role in myelination. Both in vivo and in 
vitro inhibition of p38 MAPK blocks SC demyelination, while activation of p38 MAPK 
by MKK6, a direct and specific upstream activator of p38 MAPK, is sufficient to drive 
SC demyelination and dedifferentiation following injury.  In addition, activation of p38 
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MAPK suppresses the expression of Krox-20 and induces c-jun expression (Parkinson et 
al 2004). Therefore, it is possible that c-jun and p38 MAPK function in the same pathway 
regulating the adoption of an immature SC phenotype after injury (Yang et al 2012). 
However, using pharmacological inhibitors of p38, other groups reported that p38 MAPK 
pathway is pro-myelinating. Inhibition of p38 blocked vitamin C induced Krox-20 
expression, decreased myelin gene expression, blocked myelination, and these effects 
could be partially reversed by overexpressing Krox-20 (Haines et al 2008, Hossain et al 
2012, Salzer 2008).  This seemingly paradoxical role could be the result of differential 
conditions that trigger the action of p38 MAPK. Though many of the pathways function 
as upstream regulators of c-jun and Notch, relatively little is known about how the 
integration of transcriptional mechanisms and signaling pathways affect myelination. 
However, recent work helps illustrate the role c-jun plays in SC dedifferentiation and 
neuropathy in the context of a mixed neuropathy called X-linked CMT (CMT1X) (Klein 
et al 2014). 
1.1.3. CMT1X 
CMT1X is the second most common type of CMT disease, accounting for nearly 
20% of CMT1 cases (Braathen 2012). It is caused by mutations in the gap junction beta 1 
gene (GJB1) (Gal et al 1985), which encodes the gap junction protein connexin 32 
(Cx32). As CMT1X is an X-linked dominant disorder, males are typically more severely 
affected and manifest an earlier onset of neuromuscular weakness. Milder symptoms and 
later onset in females have been hypothesized to be associated with X-inactivation 
(Murphy et al 2012b, Siskind et al 2011). Similar with CMT Type 1A (CMT1A), patients 
of CMT1X present classic symptoms of muscle weakness and atrophy starting from the 
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distal leg muscles and slowly progressing to the upper limbs (Shy et al 2007). Foot drop, 
steppage gait, and pes cavus are common in CMT1X patients. In addition, males tend to 
have split hand syndrome where the intrinsic muscles of the hand become atrophied 
(Brennan et al 2015). Based on electrophysiological findings, males usually have 
intermediate (25-45m/s) motor nerve conduction velocity (MNCV) whereas the MNCV 
is usually >35m/s in females (Saporta et al 2011). Consistently, compound muscle action 
potentials (CMAP) are reduced in patients (Birouk et al 1998), indicative of axonal loss 
in addition to demyelination. 
The gap junction protein Cx32 is a four transmembrane spanning protein that 
localizes to the Schmidt-Lantermann incisures and non-compact myelin (Scherer et al 
1995). Six Cx32 monomers form a hemi-channel, and two hemi-channels form a gap 
junction channel. Depending on the cell specific expression of various connexin family 
members, hemi-channels can be homotypic, composed of identical hemichannels, or 
heterotypic (Abrams & Freidin 2015). In the PNS, Cx32 forms homotypic channels 
(Figure 1.1.3.1, right), whereas in the central nervous system (CNS), Cx32 may form 
heterotypic channels with other members from the connexin family (Kleopa & 
Sargiannidou 2015). Cx32 gap junctions form a radial pathway that allow molecules less 
than 1 kDa to pass through the SC cytoplasm with a thousand-fold shorter distance 
(Balice-Gordon et al 1998, Scherer et al 1995). 
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Figure 1.1.3.1 Cx32 gap junction channel and reported mutations. 
Illustrations of Cx32 gap junction channel (right) and all 420 Cx32 mutations reported (left). 
Adapted from (Kleopa & Sargiannidou 2015, Panosyan et al 2017). 
The loss of function of Cx32 accounts for the peripheral symptoms in CMT1X.  
Over 400 mutations (Figure 1.1.3.1, left) of the GJB1 gene have been reported to be 
associated with CMT1X (Kleopa et al 2012, Panosyan et al 2017). Although most 
mutations are solely linked to peripheral neuropathic symptoms, the T55I and R75W 
mutants cause symptoms only in the CNS, (Kleopa et al 2002). Patients with CNS 
symptoms exhibit pathological changes in visual, acoustic and motor pathways (Bahr et 
al 1999). It is suspected that a toxic gain of function underlies the symptoms in the CNS 
(Abrams & Freidin 2015). Moreover, mutations such as R142Q and R164W cause both 






CNS manifestations depends on the ability of the mutants to form a gap junction channel 
(Abrams et al 2017). 
Cx32 deficient (Cx32def) mice are used as a mouse model of human CMT1X. 
Besides an association with liver injury, initial discovery of Cx32def mice revealed that 
these mice exhibit a progressive neuropathology. The Willecke group did not observe any 
neurological changes when Cx32def mice were observed at three month of age (Nelles et 
al 1996). However, later findings showed that axonal pathology precedes demyelination 
in this model where axonal damage started to occur at 2 months of age (Vavlitou et al 
2010). This early predemyelinating axonopathy was associated with an increase in SC c-
jun expression and a decrease in the phosphorylation state of axonal neurofilaments, a 
marker of axon damage (Klein et al 2014). Morphologically, this biochemical damage is 
reflected by an increase in smaller diameter axons without overall axon dropout, 
suggesting a decrease in the diameter of existing axons (Vavlitou et al 2010). 
Functionally, a decrease in neurofilament phosphorylation and axon diameter is 
associated with decreased nerve conduction velocity (NCV) (Hoffman et al 1987). 
During the predemyelinating neuropathy, c-jun expression correlates with an increase in 
GDNF (Klein et al 2014) since c-jun transcriptionally induces GDNF (Arthur-Farraj et al 
2012). The precise mechanism of such axonal damage independent of demyelination is so 
far unknown. However, one possible candidate would be Ca2+ since its concentration 
changes during neural activity and regulates gap junction channel opening. (Anselmi et al 
2008, De Vuyst et al 2006, Lev-Ram & Ellisman 1995).  
The second stage of CMT1X is a progressive demyelinating neuropathy that 
begins evolving around 6 months of age in the Cx32def mice. This stage of the 
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neuropathy is associated with a robust increase in c-jun expression (Klein et al 2014) 
and is driven by a SC-dependent secondary inflammation that stimulates macrophage-
mediated demyelination (Groh et al 2010, Groh et al 2015). Two key proteins 
contribute to this secondary inflammation. C-C motif chemokine (CCL2) is derived 
from SCs, is induced transcriptionally by c-jun (Wolter et al 2008) and attracts 
macrophages to infiltrate the endoneurium (Kohl et al 2010). Colony stimulating 
factor-1 (CSF-1) is secreted by endoneurial fibroblasts (Groh et al 2016, Groh et al 
2015) and activates the macrophages to promote neurodegeneration. Importantly, 
macrophages directly contribute to myelin degeneration in CMT1X (Martini & 
Willison 2016) and their role is not secondary to myelin breakdown as seen in 
Wallerian degeneration (Martini et al 2013).  
Though it is unclear how a loss-of-function of Cx32 contributes to the neuropathic 
phenotype, it is the causal lesion (Scherer & Kleopa 2012) and somatic or embryonic 
gene therapy would be the gold standard treatment. However, these approaches are 
difficult to achieve practically or ethically. Alternatively, intrathecal gene delivery of 
Cx32 in Cx32def mice can markedly improve the motor neuropathy (Kagiava et al 
2016), but the clinical path for this approach also has many hurdles. Clearly, a more 
translationally friendly approach is needed to serve the immediate needs of this 
neglected patient population. To fill this significant gap, we have explored an 
innovative small molecule approach that is based on modulating molecular chaperones 
to decrease c-jun expression and neuroinflammation in CMT1X and other peripheral 
neuropathies. 
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1.2. Heat shock proteins (Hsps) 
Heat shock proteins (Hsps) are a group of highly conserved proteins that function 
as molecular chaperones to prevent inappropriate interaction within and between 
peptides, enhance de novo protein folding, as well as promoting the refolding of 
misfolded proteins (Hartl & Hayer-Hartl 2002). Hsps can be classified into six main 
families based on their molecular weight, i.e. small Hsps (sHsps), Hsp40, Hsp60, Hsp70, 
Hsp90, and Hsp100 (Saibil 2013). Certain stress conditions, such as temperature 
elevation, trigger a program known as the heat shock response (HSR) (Figure 1.2.1). 
Upon activation, heat shock factor 1 (HSF1) dissociates from Hsp90 and undergoes 
phosphorylation and trimerization. The released HSF1 then enters the nucleus and binds 
to heat shock elements (HSE) within the promoter region of heat shock genes, leading to 
the transcription of Hsps, such as Hsp70 (Calabrese et al 2003). The HSR and induction 
of Hsps serves as a crucial cellular protective mechanism and acts as a first line of 
defense against numerous conditions that promote proteotoxic stress. 
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Figure 1.2.1: Schematic illustration of HSR.  
Various cellular stresses dissociate HSF1 from the Hsp90-HSF1 complex. Released HSF1 goes 
through phosphorylation and trimerization before entering the nucleus. HSF1 binding with HSE 
leads to transcription of Hsps and subsequent changes in the protein quality control system.  
1.2.1. Small heat shock proteins (sHsps) 
sHsps range from 12-43kDa and they share a common structure containing a 
conserved α-crystallin domain (ACD) of 80-100 amino acids, a N-terminal domain 
(NTD) and a C-terminal extension (CTE) (Franck et al 2004, Kappe et al 2003, Kriehuber 
et al 2010). sHsps can be classified based on their distribution. Class I is widely 
distributed whereas Class II is restricted to specific tissues. Hsp27 is a stress-inducible 
Class I sHsp that is ubiquitously expressed, with highest expression in heart, striated and 
smooth muscles (Taylor & Benjamin, 2005).  Besides chaperone activity, Hsp27 is also 
involved in stabilizing the cytoskeleton, autophagy and exhibits anti-apoptotic and anti-
oxidant properties (Asthana et al 2014, Mehlen et al 1996, Perng et al 2009, Taylor & 
Benjamin 2005). Mutations of the gene encoding Hsp27 lead to neuropathies such as 
distal motor neuropathy and CMT2 (Muchowski & Wacker 2005). Hsp27 has also been 
found associated with diabetic peripheral neuropathy (DPN) and results from the 
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EURODIAB Prospective Complications Study have shown an association between serum 
Hsp27 levels and the presence of a distal symmetrical polyneuropathy (Gruden et al 
2008). 
1.2.2. Hsp70 
The Hsp70s are a family of ubiquitously expressed Hsps that are involved in a 
number of processes, including the folding of nascent peptides, refolding of misfolded 
peptides and protein trafficking (Lackie et al 2017). There are 13 gene products (Table 
1.2.2.1) in the human Hsp70 family and they are encoded by a multigene family, 
including 17 genes and 30 pseudogenes (Radons 2016). Widely studied forms include the 
cytosolic heat shock cognate 70 (Hsc70), stress-induced cytosolic Hsp72 (Hsp70 in 
mice), glucose-regulated protein 78 (Grp78) located in the endoplasmic reticulum (ER) 
and mitochondrial Grp75 (Fink 1999). 
Table 1.2.2.1: The human Hsp70 family. 
Protein Alternative 
names 
Gene Cellular localization Stress-
inducible 
Hsp70-1a Hsp70, Hsp72, 
Hsp70-1 
HSPA1A Cytosol, nucleus, cell 
membrane 
√ 
Hsp70-1b Hsp70, Hsp72, 
Hsp70-2 
HSPA1B Cytosol, nucleus √ 
Hsp70-1t Hsp70-hom, 
Hsp70-1L 
HSPA1L Cytosol, nucleus × 
Hsp70-2 Hsp70.2 HSPA2 Cytosol, nucleus,  
cell membrane 
× 
Hsp70-5 Bip, Grp78 HSPA5 ER × 
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Hsp70-6 Hsp70B’ HSPA6 Cytosol √ 
Hsp70-7 Hsp70B HSPA7 Blood microparticles √ 
Hsp70-8 Hsc70, Hsc71, 
Hsp71, Hsp73 
HSPA8 Cytosol, nucleus,  
cell membrane 
× 





HSPA9 Mitochondria, nucleus × 
Hsp70-12A FLJ13874, 
KIAA0417 
HSPA12A Intracellular × 
Hsp70-12B RP23-32L15.1, 
2700081N06Rik 
HSPA12B Endothelial cells, intracellular, 
blood plasma 
× 
Hsp70-13 Stch HSPA13 ER, microsomes × 
Hsp70-14 Hsp70L1 HSPA14 Cytosol, membrane √ 
Modified from (Radons 2016) 
All Hsp70s share a conserved structure, an N-terminal ATPase domain and a C-
terminal substrate binding domain (Tavaria et al 1996), joined together by a short, 
flexible linker (Jiang et al 2005). The 40kDa N-terminus regulates client association and 
the 25kDa C-terminal recognizes the hydrophobic residues of substrate proteins (Bukau 
et al 2006, Rudiger et al 1997). Hsp70 is found in most cellular compartments, and 
together with its co-chaperone Hsp40, facilitates the stabilization and folding of 
numerous substrates (Bukau & Horwich 1998). Although Hsp70 is mostly found as a 
monomer (Bertelsen et al 2009), recent evidence suggests that it can form an antiparallel 
dimer and aid client protein transfer from Hsp70 to Hsp90. Hsp40 stabilizes the Hsp70 
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dimer and the transfer of client proteins to Hsp90. In addition, post-translational 
modifications, such as phosphorylation and acetylation stabilize the dimerization of 
Hsp70 (Morgner et al 2015).  
As Hsps play a role in refolding and degradation of denatured proteins, it is not 
surprising that Hsp70s levels are elevated in protein aggregation diseases, such as 
Alzheimer’s disease (AD) (Hamos et al 1991, Perez et al 1991). Substantial evidence 
suggests that an elevated level of Hsp70 could ameliorate the Aβ burden of AD. 
Overexpression of Hsp70 protects primary neurons against intracellular Aβ42-induced 
toxicity (Magrane et al 2004). Intranasal administration of Hsp70 ameliorated spatial 
memory deficits and cognitive abnormalities in AD mouse models (Bobkova et al 2014). 
GRP78, the ER isoform of Hsp70, binds to immature but not mature amyloid precursor 
protein (APP) and decreases the secretion of Aβ40 and Aβ42 (Yang et al 1998). Moreover, 
upregulation of GRP78 by acetyl-L-carnitine (ALCAR), an endogenous mitochondrial 
membrane compound that helps maintain mitochondrial function, reduced Aβ induced 
protein oxidation, lipid peroxidation and neuronal loss (Abdul et al 2006). Thus, 
modulating the expression of Hsp70 paralogs may provide an avenue to treat AD, as well 
as other neurodegenerative diseases as discussed below. 
1.2.3. Hsp70 cochaperones 
 Hsp40 1.2.3.1.
The Hsp40 family, often referred to as the J protein family, function as co-
chaperones of Hsp70. Structurally, they share the same conserved J domain that contains 
about 70 amino acids. Hsp40s can be classified into three classes based on their structure. 
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Class I proteins have an N-terminal J domain, a Gly Phe-rich region, a zinc finger motif 
and a C-terminal extension. Class II proteins lack the zinc finger motif and Class III 
contains all proteins with other structures (Kampinga & Craig 2010). As an Hsp70 
cochaperone, Hsp40 first binds to the client protein and prevents its degradation and then 
delivers it to Hsp70 for further processing. In addition, Hsp40 can simulate Hsp70 
ATPase activity. The His, Pro and Asp domain (HPD) is crucial for stimulation of Hsp70 
ATPase activity and aiding Hsp70 function. The exact mechanism is unknown but it is 
proposed that the J domain provides a surface for Hsp70 to interact with the substrate 
(Greene et al 1998, Jiang et al 2007). ATP hydrolysis can be stimulated by both Hsp40 
and the client and causes a conformational change of Hsp70 to stabilize client protein 
interaction. Hsp40 then leaves and nucleotide exchange factor (NEF) binds to ADP-
bound Hsp70 and dissociates ADP. ATP then binds to Hsp70 and the client protein is 
released following ATP hydrolysis. If the desired conformation of the client protein is not 
achieved, the above process is repeated (Kampinga & Craig 2010). Various members of 
the Hsp40 family have been identified to be involved in the progression of Parkinson’s 
Disease (PD) (Hasegawa et al 2017) and upregulation of Hsp40 or Hsp40/Hsp70 may 
provide a therapeutic strategy to these protein-folding diseases. 
 Heat shock cognate protein 70 (Hsc70) interacting protein (CHIP) 1.2.3.2.
Carboxy terminus of heat shock cognate protein 70 (Hsc70) interacting protein 
(CHIP) is an E3 ligase that mediates the proteasomal clearance of Hsp70 substrates by 
directly binding to the C-terminus of Hsp70 (Dickey et al 2007c). CHIP contains three 
tetratricopeptide repeat (TPR) motifs within its N-terminus, a middle domain and a C-
terminal U-box domain (Ballinger et al 1999, Zhang et al 2005). As an important member 
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of the ubiquitin-proteasome system (UPS), CHIP has dual functions; it is both a co-
chaperone of Hsp70 and an E3 ligase. CHIP associates with Hsp70 through the TPR 
domain, and facilitates the transfer of polyubiquitin chains to substrates (Jiang et al 
2001). CHIP also mediates the crosstalk between Hsps and the UPS through Bcl-2 
associated athanogene 1 (BAG1), a protein that binds to the 26S proteasome and assists 
in the degradation of specific Hsp substrates (Lüders et al 2000). Several lines of 
evidence suggest that CHIP and its associated chaperone complex play a key role in 
regulating Aβ and tau levels. Kumar et al. observed that CHIP could promote the 
association of ubiquitin with βAPP and forced CHIP and Hsp70/90 expression reduced 
steady state cellular Aβ levels and accelerated its degradation (Kumar et al 2007). CHIP 
can also interact with Hsp70/90 directly and promote the ubiquitination of tau (Petrucelli 
et al 2004). 
1.2.4. Hsp90 
Hsp90 is another important member of the Hsp family (Smith et al 1998), which 
helps stabilize misfolded proteins and regulates a variety of signaling proteins, including 
steroid hormone receptors, tyrosine receptors, nitric oxide synthase and calcineurin 
(Young & Hartl 2002). Humans have two HSP90 genes that encode constitutively 
expressed HSP90β and stress inducible HSP90α (Shen et al 1997, Zhang et al 1999). 
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Figure 1.2.4.1: The structure and conformational cycle of Hsp90.  
Hsp90 contains an NTD, a flexible linker, MD and CTD. The MEEVD within the CTD is 
important for interaction with co-chaperones. Upon ATP binding, Hsp90 homodimer transits 
from an open state to an intermediate state where the lid is closed. Closed 1 state refers to the 
interaction of NTDs of the monomers and then twisting of the monomers (closed state 2). ATP is 
then hydrolyzed, releasing ADP and Pi, and Hsp90 returns to the open state. Co-chaperones, 
HOP, PPIase, AHA-1, CDC37 and p23 assist at different stages. Adapted from (Schopf et al 
2017). 
Hsp90 contains three conserved domains, an NTD, which contains the ATPase 
activity a middle domain (MD) responsible for binding with clients, and a C-terminal 
domain (CTD), which is important for dimerization (Harris et al 2004, Prodromou et al 
1997). The Met-Glu-Glu-Val-Asp (MEEVD) motif within the C-terminal tail interacts 
with the TPR domains of co-chaperones (Buchner 1999). Binding with ATP induces a 
conformational change of Hsp90, to transit the protein from the V- shape open state to an 










of the monomers interact. ATP hydrolysis takes place after the monomers twist in the 
closed 2 state. ADP and Pi are then released and Hsp90 returns to the open state 
(Cunningham et al 2008, Meyer et al 2003) (Figure 1.2.4.1).  
Co-chaperones interact with Hsp90 at different stages. Hsc70/Hsp90-organinzing 
protein (HOP) binds to Hsp90 and stabilizes the open state (Li et al 2011). HOP is also 
responsible for the transfer of clients between Hsp70 and Hsp90 (Wegele et al 2006). 
CDC37 binds to Hsp90 at the open state and is important for the recruitment of client 
kinases specifically (Li et al 2011, Taipale et al 2012, Taipale et al 2014). Peptidyl-prolyl 
cis-trans isomerases (PPIases) bind to Hsp90 at all stages whereas activator of Hsp90 
ATPase homologue1 (AHA1) binds at closed 1 state and p23 at closed 2 state to facilitate 
ATP hydrolysis (Li et al 2011).  
The expression and activity of Hsp90 can be regulated through multiple 
mechanisms. Stress dissociates Hsp90 from the Hsp90/HSF1 complex where HSF1 is 
released and leading to a subsequent increase in Hsp90 transcription and expression (Shi 
et al 1998). Not surprisingly, PTMs regulate the activity of Hsp90. Phosphorylation slows 
down the conformational cycle of Hsp90 and affects its interaction with clients and co-
chaperones (Mollapour & Neckers 2012, Soroka et al 2012). Acetylation of Hsp90 
inhibits its ability to bind co-chaperones (Kovacs et al 2005) while  S-nitrosylation 
impairs the ATPase activity of Hsp90 (Martinez-Ruiz et al 2005). SUMOylation of one 
Hsp90 protomer is crucial for the recruitment of AHA-1 but not other co-chaperones 
(Mayer & Le Breton 2015, Mollapour et al 2014).  
Hsp90 client proteins have been reported to be involved in a number of diseases, 
including cancer (Vartholomaiou et al 2016), neurodegenerative diseases (Dickey et al 
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2007a, Geller et al 2013, Geller et al 2012) and infectious diseases (Geller et al 2012, 
Roy et al 2012). The stabilization of certain client proteins by Hsp90 generally 
contributes to the progression of the disease, such as AD and cancer. Thus, inhibiting 
Hsp90 could serve as a therapeutic strategy in numerous diseases and we have focused on 
the role of modulating Hsp90 in treating peripheral neuropathies. 
1.3. Targeting Hsps to Treat Peripheral Neuropathies 
Peripheral neuropathies are generally classified as axonal or demyelinating and 
manifest from diverse etiologic backgrounds, e.g., genetic, metabolic, autoimmune, drug 
or trauma-induced. Axonal and demyelinating peripheral neuropathies form the most 
common group of neurologic disorders and their medical management continues to 
present a significant medical liability as they affect well over 20 million people in the US 
alone (Hoke 2012). Peripheral neuropathies are often associated with painful paresthesias 
that include tingling, prickling or burning sensations, as well as numbness and muscle 
weakness if motor fibers are involved (Edwards et al 2008). On the molecular side, loss 
of axonal contact during nerve injury causes myelinated SCs to arrest myelination and 
dedifferentiate into a phenotype similar to an immature premyelinating SC (Parkinson et 
al 2008). The dedifferentiated SCs express molecules distinct to this phenotype, such as 
L1, GDNF, and N-cadherin, in addition to the reactivation of the transcription factor c-
jun (Jessen & Mirsky 2008). Demyelinated axons are a common feature in human 
neuropathies, such as CMT1A and CMT1X (Hutton et al 2011), Refsun disease (Scherer 
& Wrabetz 2008), chronic inflammatory demyelinating polyneuropathy (Hur et al 2011) 
and diabetic peripheral neuropathy (Behse et al 1977). 
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1.3.1. Targeting Hsp90 to Modulate Hsp70 Expression and Treat Peripheral 
Neuropathies 
Since pharmacologically modulating the HSR can serve as a powerful approach to 
ameliorate neurodegenerative diseases, modulating molecular chaperones may prove 
beneficial in managing certain neuropathies (Pratt et al 2015). Multiple lines of evidence 
suggest that modulating Hsp70 is beneficial in a variety of diseases associated with 
abnormal protein aggregates, such as AD (Magrane et al 2004) and PD (Aridon et al 
2011). Unfortunately, small molecule approaches to directly activate or inhibit Hsp70 are 
not sufficiently evolved for clinical applications (Assimon et al 2013). On the other hand, 
Hsp70 expression can be indirectly modulated by exploiting Hsp90 as a drug target. 
However, effective pharmacologic control of Hsp90 to attain a specific therapeutic 
efficacy requires dissociating cytotoxicity, due to inhibiting the folding of client proteins, 
from cytoprotection induced by activation of the HSR. 
 Numerous small molecules have been designed that function as N-terminal 
Hsp90 inhibitors (Garg et al 2016). N-terminal Hsp90 inhibitors act by blocking the 
ATPase activity of Hsp90. Inhibiting ATP hydrolysis blocks protein folding and 
promotes client protein degradation. Since many Hsp90 client proteins are oncoproteins, 
incomplete folding promotes their degradation and N-terminal Hsp90 inhibitors are being 
evaluated as chemotherapeutics (Miyata et al 2013). Unfortunately, drug concentrations 
that induce client protein degradation and cytotoxicity also release HSF1 and induce a 
HSR. This upregulates the expression of chaperones, such as Hsp70 and Hsp90, which 
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can facilitate oncoprotein refolding and antagonize the goal of promoting tumor 
cytotoxicity (Peterson & Blagg 2009).  
While increasing Hsp70 may be a problem for chemotherapy, this aspect of 
targeting Hsp90 may be useful to improve neurodegenerative diseases associated with 
protein aggregation. In this respect, N-terminal Hsp90 inhibitors can decrease tau 
aggregation in AD (Dickey et al 2007a, Luo et al 2007b), huntingtin protein in motor 
neurons (Waza et al 2005) and peripheral myelin protein 22 (PMP22) aggregates in SCs 
of CMT1A mice (Chittoor-Vinod et al 2015). However, this efficacy does not avoid the 
issue related to dissociating client protein degradation from induction of the HSR. Now 
the converse caveat exists, promoting client protein degradation will antagonize the 
neuroprotective phenotype. Therefore, an effective Hsp90 modulator for treating 
neurodegeneration requires a drug with a sufficient therapeutic window that can 
upregulate Hsp70 but induce minimal client protein degradation to antagonize the 
protective HSR. Though current N-terminal chemotherapeutics have been unable to 
adequately divest these competing actions, the chemical biology of targeting the C-
terminus of Hsp90 has identified such compounds (Anyika et al 2016, Kusuma et al 
2012b). 
The antibiotic novobiocin weakly binds the Hsp90 C-terminal domain (Marcu et al 
2000) and systematic modification of the coumarin ring of novobiocin identified 
compounds such as KU-32 and KU-174 (Figure 1.3.1.1A and B). KU-174 is an effective 
cytotoxic compound that contains a biaryl ring system that is necessary to induce 
degradation of client proteins such as Akt, but without promoting the expression of 
Hsp70 (Samadi et al 2011). The noviose sugar is critical for these novobiocin derivatives 
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to interact with the C-terminal domain of Hsp90 (Ghosh et al 2015) but differences in the 
side chains dictate distinct biologic outcomes. In KU-174, its cytotoxicity is related to the 
presence of the bulky biaryl side chain that binds to the co-chaperone Aha 1. Aha 1 
increases the N-terminal ATPase activity of Hsp90 and disrupting this interaction blocks 
protein folding and facilitates client protein degradation (Ghosh et al 2015). In contrast, 
KU-32 contains an ethyl acetamide substitution and induces Hsp70 at concentrations 
~500 fold lower than those that promote client protein degradation (Urban et al 2010). 
The neuroprotective phenotype promoted by KU-32 is highly dependent on the length of 
the side chain; increasing the length of the alky chain inverts the biologic response 
leading to inhibition Hsp90-dependent refolding activity, disrupting the interaction 
between Hsp90 and Aha1 and producing a linear increase in anti-proliferative activity 
(Ghosh et al 2016).  
Figure 1.3.1.1: Structures of novologues. 
Structures of KU-32 (A), KU-174 (B) and KU-596 (C). 
Efforts to further optimize KU-32 led to substitution of a fluorinated biphenyl ring 
for the coumarin moiety and the identification of KU-596 (Figure 1.3.1.1C) as a new 
class of C-terminal analogs called novologues (Kusuma et al 2012b) Like KU-32, KU-
596 does not bind to Hsp70 and does not induce client protein degradation at 
concentrations necessary for neuroprotective efficacy. Thus, targeting the C-terminal of 
Hsp90 provides a sufficient therapeutic window that divests cytotoxicity from 
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cytoprotection and may facilitate the development of potentially effective 
neurotherapeutics to treat peripheral neuropathies. 
1.3.2. Modulating Hsp70 to Attenuate Protein Aggregates in CMT1A 
Historically, targeting Hsp70 to treat neurodegenerative diseases has largely focused 
on disease etiologies associated with protein aggregation (Pratt et al 2015, Pratt et al 
2014). For example, decreasing PMP22 aggregates in CMT1A (Okamoto et al 2013, 
Rangaraju et al 2008a) or neurofilaments in CMT type 2E (CMT2E) (Gentil et al 2013, 
Tradewell et al 2009). CMT disease is the most prevalent inherited neuropathy, and is 
caused by mutations in over 50 genes involved in myelin formation and maintenance. 
About 90% of diagnosed CMT patients have a mutation in one of four genes, PMP22, 
MPZ, GJB1 and MFN2 (Latour et al 2006, Murphy et al 2012a, Saporta et al 2011). 
Depending on the neurophysiological manifestations, CMT can be divided into 
demyelinating (CMT1 and CMT4) and axonal CMT (CMT2) (Brennan et al 2015). 
Among all subtypes, the autosomal dominant CMT1A accounts for 60%-70% of all CMT 
patients (Saporta et al 2011). CMT1A is caused by duplication of a 1.5Mb region on the 
short arm of chromosome 17 that encodes a major component of the peripheral myelin, 
PMP22 (Lupski et al 1991, Lupski & Garcia 1992). As a demyelinating form of CMT, 
MNCV of CMT1A patients is often less than 38m/s while compound muscle action 
potential (CMAP) is rarely affected. Sensory action potentials are reduced or absent 
(Tazir et al 2014, Vallat et al 2004). Classical CMT symptoms include distal weakness, 
atrophy, and loss of sensation and foot deformities. Despite intensive research, there is 
currently no cure and treatment relies only on physical therapy, orthopedic surgeries, 
supportive braces and pain management (Brennan et al 2015). Though CMT1A is not 
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lethal, the quality of life of CMT1A patients is impacted in all dimensions. Many studies 
showed that patients with CMT have significantly lower health-related quality of life 
scores (El-Abassi et al 2014), which correlates with pain and muscle weakness (Abresch 
et al 2002, Abresch et al 2001, Burns et al 2010, Calvert et al 2013, Carter et al 1995, 
Padua et al 2010, Redmond et al 2008). Thus, a quest for potential target for 
pharmacological intervention is of importance. 
PMP22 is an indispensable component of the myelin. PMP22-deficient mice 
showed delayed onset of myelination, severe demyelination, and functional impairment 
similar to hereditary neuropathy with liability to pressure palsies (Chance et al 1993, 
Perea et al 2001). Overexpressed PMP22 will overload the trafficking system and 
proteasome degradation pathway and form aggregates in a late Golgi compartment 
(Goldberg 2003, Niemann et al 1999), resulting in demyelination as seen in CMT1A. 
Molecular chaperones, ubiquitin-proteasomal and lysosomal pathways are found 
consistently elevated in the affected nerves, but overtime, they fail to prevent the 
accumulation of PMP22 aggregates (Chittoor et al 2013, Fortun et al 2003, Ryan et al 
2002). Following this thought, one approach in trying to find a potential treatment for 
CMT1A focuses on clearing up the protein aggregates of PMP22 with the help of 
molecular chaperones.  
Geldanamycin, an N-terminal Hsp90 inhibitor, or simply heat shock treatment 
upregulated the expression levels of Hsps, especially Hsp70, and reduced aggresome 
formation (Fortun et al 2007, Rangaraju et al 2008b). Another Hsp90 inhibitor, EC137 
showed similar effects in SC-DRG co-cultures prepared from CMT1A mouse model 
(Rangaraju et al 2008b). Furthermore, the same lab reported that the Hsp90 inhibitor 
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BIIB021 helps attenuate the proteasome dysfunction in cells from a CMT1A patient in an 
Hsp70 dependent manner (Chittoor-Vinod et al 2015). Taken together, inducing Hsp70 
seems a promising therapeutic strategy for CMT1A.  
Though targeting Hsp70 to treat neurodegenerative diseases has been limited to 
etiologies associated with protein aggregation, over the last seven years, we have 
unambiguously demonstrated that novologue therapy decreases inflammation, increases 
the density of unmyelinated sensory fibers and reverses electrophysiologic, bioenergetic 
and psychosensory deficits of diabetic peripheral neuropathy (DPN) in an Hsp70-
dependent manner (Ma et al 2014, Ma et al 2015, Urban et al 2010, Urban et al 2012, 
Zhang et al 2012). Since the etiology of DPN is not linked to protein aggregation, this 
work has presented a new paradigm that modulating Hsp70 is inherently neuroprotective 
and may ameliorate DPN by increasing neuronal tolerance to diabetic stress (Calcutt 
2010). The ability of Hsp70 to treat neuropathies with differing etiologies is linked to 
its role in refolding and/or removing damaged or disease-modifying proteins in a cell 
distinct manner. This lack of mechanistic selectivity for neuroprotection by Hsp70 is not 
a drawback but represents a flexible paradigm for translational development. Thus, an 
effective therapeutic approach for treating complex, chronic neurodegenerative diseases 
may not require targeting a single pathway or protein that contributes to disease onset or 
progression (Dobrowsky 2016), but benefit from increasing the activity of inherently 
neuroprotective pathways associated with Hsp70. 
1.3.3. Modulating Chaperones to Treat Diabetic Peripheral Neuropathy 
According to the Center for Disease Control and Prevention, 30.3 million (about 
9.4% US population) people had diabetes in 2017. Diabetes is associated with the onset 
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of a variety of complications including autonomic neuropathy, retinopathy, nephropathy, 
and DPN (Balakumar et al 2009). DPN is the most prevalent complication of diabetes 
and often manifests as a distal, symmetric, sensorimotor neuropathy that exhibits a 
stocking-glove distribution since symptoms start in the feet or hands and progress 
proximally. DPN arises due to the degeneration of small, unmyelinated or thinly 
myelinated sensory fibers that mediate pain/temperature sensation (C and Aδ fibers) and 
larger myelinated fibers that are involved primarily in tactile sensation (Aβ fibers) 
(Zochodne 2007). Diabetes-induced changes in unmyelinated C-fibers lead to the 
development of small fiber neuropathy that often produces localized painful (positive) 
symptoms while degeneration of thinly myelinated Aδ fibers produces a more diffuse 
pain. Progressive neurodegeneration often resolves the neuropathic pain, but decreased 
response thresholds (Lennertz et al 2011) and loss of epidermal innervation of C-fibers in 
the feet (Beiswenger et al 2008) can contribute to insensate neuropathic symptoms such 
as thermal hypoalgesia. Similarly, degeneration of Aβ fibers leads to a loss of vibration 
and tactile sensation (Christianson et al 2007) with eventual segmental demyelination in 
long-term DPN (Zochodne 2007). Patients with insensate DPN are at high risk to develop 
foot ulcerations and DPN is the number one cause of non-traumatic lower-limb 
amputations (Callaghan et al 2012, Gordois et al 2003, Margolis et al 2011). Current 
FDA approved treatments for DPN target mainly painful neuropathy (Griebeler et al 
2014) but no FDA approved pharmacologic options are available for patients with 
insensate neuropathy (Calcutt et al 2009). 
In individuals with Type 1 diabetes, data from the Diabetes Control and 
Complications Trial provided substantial support for the hypothesis that DPN develops 
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because of increased blood glucose levels (DCCT  Research Group 1988, DCCT 
Research Group et al 1993). However, this relationship is not as central to the 
pathogenesis of DPN in individuals with Type 2 diabetes since insulin 
deficiency/resistance and dyslipidemia may be critical contributors (Kim & Feldman 
2012, Wiggin et al 2008). Moreover, hyperglycemia and dyslipidemia provoke 
downstream alterations in numerous pathways that have been well characterized to 
contribute to DPN. This includes enhanced activity of the polyol pathway, protein kinase 
C and poly(ADP-ribose) polymerase, an increase in inflammatory pathways, protein 
modification by advanced glycation end products and N-acetylglucosamine, increased 
oxidative and nitrosative stress, decreased neuronal mitochondrial bioenergetics and a 
reduction in neurotrophic factor support (Feldman et al 2017, Pop-Busui et al 2016).  
Although targeting any one of these pathways in animal models of DPN can 
improve neuropathic endpoints, this success has not resulted in any translational 
advancements in treating human DPN. One difficulty in treating DPN is that the 
contribution of these various metabolic insults to the onset of the neuropathy does not 
necessarily occur in a temporally and/or biochemically uniform fashion.  In the absence 
of identifying a convergent node critical to disease progression, it is likely that multiple 
pathways lead to the progressive distal axonopathy and poor regenerative potential that 
characterize diabetic neuropathy. Alternatively, an effective therapeutic approach for 
treating complex, chronic neurodegenerative diseases may benefit from increasing the 
activity of inherently neuroprotective pathways associated with molecular chaperone 
signaling.  For example, overexpression of Hsp70 can reduce reactive oxygen species 
(ROS) under hypoxia (Guo et al 2007) and improve mitochondrial function in neurons 
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after ischemia (Xu et al 2010). Similarly, we have shown C-terminal Hsp90 modulators 
can improve DPN in an Hsp70-dependent manner.  
KU-32 was the first C-terminal Hsp90 modulator shown to reverse a sensory 
hypoalgesia and loss of intra-epidermal nerve fibers in diabetic mice, a morphologic 
marker of small fiber damage in DPN (Urban et al 2010, Urban et al 2012). Using Hsp70 
knockout (KO) mice, this study also linked Hsp70 to drug efficacy. Although the absence 
of Hsp70 did not interfere with the development of DPN in Hsp70 KO mice, it did 
abrogate the ability of KU-32 to improve the sensory hypoalgesia. Mechanistically, KU-
32 improved mitochondrial bioenergetic deficits in models of type 1 and type 2 diabetes 
in an Hsp70 dependent manner (Ma et al 2014). In addition, Hsp70 induction correlated 
with decrease in inflammatory markers and improvement in painful neuropathy (Ortmann 
& Chattopadhyay 2014, Yoon et al 2015).  
KU-596 is a next generation novologue that showed greater Hsp70 induction and 
a 14-fold greater efficacy in preventing glucose induced toxicity of sensory neurons 
(Kusuma et al 2012b). RNA-sequencing results from diabetic mice receiving weekly 
doses of KU-596 showed that it reversed a diabetes-induced increase in inflammatory in 
a largely Hsp70-dependent manner (Ma et al 2015). Taken together, this indicates that 
Hsp70 inducers may provide a promising approach in the treatment of DPN and other 
neuropathies. 
1.3.4. Modulating Hsp70 to Treat Demyelinating Neuropathies 
The goal of this work was to assess whether KU-596 could improve a 
demyelinating neuropathy whose etiology was unassociated with protein aggregation, but 
linked to changes in c-jun expression and inflammation. To this end, we employed two 
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mouse models of demyelinating neuropathy to test the effects of in vivo treatment with 
KU-596 on biochemical, physiological and morphological measures of neuropathy. The 
first mouse model we used is the MPZ-Raf mice and is described in Chapter 2. These 
mice express a tamoxifen inducible, estrogen receptor fused with Raf kinase, downstream 
of the SC-specific promoter, P0. After a series of tamoxifen injections, MPZ-Raf mice 
displayed a demyelinating neuropathy induced specifically by SC c-jun. This mouse line 
was crossed with Hsp70KO mice to study the role of Hsp70 in drug action. Studies 
conducted with these models provided proof-of principle that KU-596 may be effective in 
treating demyelinating neuropathies. Though powerful, this transgenic mouse model has 
certain drawbacks. For example, the motor deficits occurred within the first 10 days, 
which makes it extremely difficult to optimize the experimental design to maximize the 
effects of KU-596. More importantly, this model does not mimic any complexities in 
axonal/demyelinating neuropathies, not to mention it does not recapitulate any real 
human diseases. To circumvent these issues, we complemented our study with Cx32def 
mice, a mouse model of CMT1X.  
As described in Section 1.1.3 and Chapter 3, recent evidence suggests that elevated 
c-jun expression is associated with the progression of the disease (Klein et al 2014). The 
mechanistic goal of these studies was to test whether KU-596 could ameliorate the 
neurodegeneration and examine if regulating c-jun expression was involved in the 
mechanism of drug action and determine if Hsp70 was also critical for drug efficacy in 
the context of the genetic deletion of Cx32.  Our translational goal is to identify if KU-
596 may provide an avenue for the therapeutic management of CMT1X since this 
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Chapter 2. Targeting Heat Shock Protein 70 to Ameliorate c-Jun 
Expression and Improve Demyelinating Neuropathy 
Reprinted (adapted) with permission from Zhang, Z., Li, C., Fowler, S. C., Zheng, Z., 
Blagg, B.S.J., and Dobrowsky, R.T. (2018) Targeting Heat Shock Protein 70 to 
Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy. ACS Chem 
Neurosci. 9, 381-390. Copyright (2018) American Chemical Society. 
 
Abstract 
Increased expression of the c-jun transcription factor occurs in a variety of human 
neuropathies and is critical in promoting Schwann cell (SC) dedifferentiation and loss of 
the myelinated phenotype. Using cell culture models, we previously identified KU-32 as 
a novobiocin-based C-terminal heat shock protein 90 (Hsp90) inhibitor that decreased c-
jun expression and the extent of demyelination. Additional chemical optimization has 
yielded KU-596 as a neuroprotective novologue whose mechanistic efficacy to improve a 
metabolic neuropathy requires the expression of Hsp70. The current study examined 
whether KU-596 therapy could decrease c-jun expression and improve motor function in 
an inducible transgenic model of a SC-specific demyelinating neuropathy (MPZ-Raf 
mice). Treating MPZ-Raf mice with tamoxifen activates the MAPK kinase pathway, 
increases c-jun expression and produces a profound demyelinating neuropathy 
characterized by a loss of motor function and paraparesis. KU-596 therapy did not 
interfere with MAPK activation but reduced c-jun expression, significantly improved 
motor performance and ameliorated the extent of peripheral nerve demyelination in both 
prevention and intervention studies. Hsp70 was necessary for the drug’s neuroprotective 
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efficacy since MPZ-Raf × Hsp70 knockout mice did not respond to KU-596 therapy. 
Collectively, our data indicate that modulating Hsp70 may provide a novel therapeutic 
approach to attenuate SC c-jun expression and ameliorate the onset of certain 




Peripheral neuropathies are generally classified as axonal or demyelinating and 
manifest from diverse etiologic backgrounds, e.g., genetic, metabolic, autoimmune, drug 
or trauma-induced. Demyelinating neuropathies are typically characterized by damaged 
myelin but intact axons. At the molecular level, recent evidence suggests that the c-jun 
transcription factor is a critical node in regulating demyelination (Parkinson et al 2008). 
Interestingly, upregulation of c-jun is reported in human axonal and demyelinating 
neuropathies including Charcot-Marie-Tooth disease (CMT) Type 1A (CMT1A), X-
linked CMT (CMT1X) and chronic inflammatory demyelinating polyneuropathy (Hur et 
al 2011, Hutton et al 2011).  However, it remains unclear if targeting c-jun may provide a 
viable approach to ameliorate certain neuropathies. 
c-Jun is highly expressed in immature Schwann cells (SC) and is downregulated as 
SC begin to myelinate (Mirsky et al 2008). Although c-jun is minimally expressed in 
healthy nerves, it is rapidly upregulated in pathological or injured nerves.  During nerve 
injury, loss of axonal contact causes myelinated SC to arrest myelination and 
dedifferentiate into an immature phenotype (Parkinson et al 2008). c-Jun is required for 
SC dedifferentiation since its SC-specific deletion results in a marked delay in the rate of 
myelin sheath degradation (Parkinson et al 2008). However, despite the role of c-jun-N-
terminal kinase (JNK) in regulating the transcriptional activity of c-jun by 
phosphorylation, c-jun-mediated demyelination appears to be independent of this 
pathway (Parkinson et al 2008, Raivich & Behrens 2006). Thus, pharmacological 
approaches that antagonize c-jun expression may yield a novel strategy to treat certain 
human neuropathies. To this end, we have found that modulating molecular chaperones 
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can antagonize the expression of c-jun and subsequent demyelination in SC-DRG (dorsal 
root ganglia) co-cultures (Li et al 2012b).  
Molecular chaperones, such as heat shock proteins 70 (Hsp70) and Hsp90, function 
in the folding of nascent polypeptides, refolding of misfolded proteins and the clearing of 
damaged proteins or protein aggregates (Pratt et al 2015, Pratt et al 2014). Hsp90 
contains N- and C-terminal nucleotide-binding domains that are joined by a middle 
domain, which binds co-chaperones, client proteins and the transcription factor, heat 
shock factor 1 (HSF1) (Ciglia et al 2014). The C-terminal domain is essential for forming 
a functional Hsp90 homodimer and the N-terminal ATPase is required for the protein’s 
chaperone activity (Ciglia et al 2014, Hall et al 2014). Through its intrinsic ATPase 
activity and interaction with co-chaperones, isomerases and immunophilins, Hsp90 
directs the folding of “client” proteins into their biologically active conformations 
(Assimon et al 2013, Dekker et al 2015, Peterson & Blagg 2009).  Inhibiting this ATPase 
activity can increase client protein degradation and may be useful in treating certain 
malignancies. However, Hsp90 also serves another important biologic role since it is a 
direct regulator of the cellular heat shock response (HSR) by binding to HSF1 and 
suppressing its transactivating capacity (Vihervaara & Sistonen 2014). Upon exposure to 
proteotoxic stress or binding of small molecules, conformational changes in Hsp90 
disrupt its interaction with HSF1 and lead to the transcriptional induction of 
cytoprotective proteins, such as Hsp70.  
Modulating Hsp70 expression is emerging as an attractive target to improve 
neurodegenerative diseases associated with protein aggregation. In this respect, N-
terminal Hsp90 inhibitors have been reported to decrease tau aggregation in Alzheimer’s 
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disease (Dickey et al 2007a, Luo et al 2007b), huntingtin protein in motor neurons (Waza 
et al 2005) and PMP22 aggregates in CMT1A mice (Chittoor-Vinod et al 2015). 
However, many N-terminal inhibitors are unable to dissociate client protein degradation 
from induction of the HSR. This limitation can increase the degradation of Hsp90 client 
proteins necessary for normal cell homeostasis and antagonize the neuroprotective 
phenotype. Therefore, an effective Hsp90 modulator for treating neurodegeneration 
requires a drug with a sufficient therapeutic window that can upregulate Hsp70 but 
induce minimal client protein degradation to antagonize the protective HSR. To this end, 
we have identified a series of compounds called novologues that bind to the C-terminal 
domain of Hsp90 and induce Hsp70 at concentrations ~500 fold lower than those that 
promote client protein degradation (Kusuma et al 2012b, Urban et al 2010).   
KU-596 (Figure 2.3.1.1A) is a highly bioavailable novologue that has shown 
efficacy in improving sensory deficits in models of diabetic peripheral neuropathy (Ma et 
al 2015). The current study assessed the ability of KU-596, to prevent c-jun-induced 
demyelination in two transgenic mouse models of a SC-specific demyelinating motor 
neuropathy (Napoli et al 2012a). These proof-of-concept data suggest that attenuating c-
jun induction may provide a novel therapeutic strategy in treating certain demyelinating 
neuropathies.   
2.2. Materials and Methods 
Corn oil (CO), p-phenylenediamine and dimethyl sulfoxide (DMSO) were purchased 
from Sigma-Aldrich (St. Louis, MO). Tamoxifen (TMX) was purchased from Cayman 
Chemical (Ann Arbor, MI). KU-596, N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-
6,6-dimethyltetrahydro-2H-pyran-2-yl)oxy)-3′-fluoro-[1,1′-bi- phenyl]-2-yl)ethyl)-
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acetamide was synthesized as previously described (Kusuma et al 2012b). Compound 
purity routinely exceeded 95%. 
c-Jun antibody was purchased from Cell Signaling Technology (#9165, Danvers, 
MA). Biotinylated Hsp70 antibody was purchased from Enzo Life Sciences (#ADI-SPA-
810B, Farmingdale, NY). β-actin antibody, GAPDH antibody, goat anti-mouse HRP 
conjugated secondary antibody and goat anti-rabbit HRP conjugated secondary antibody 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit Alexa 
Fluor-647 conjugated secondary antibody, streptavidin-HRP and Diamond prolong 
antifade mounting solution with 4',6-diamidino-2-phenylindole (DAPI) were purchased 
from Thermo-Fisher Scientific Inc. (Grand Island, NY).  
Tissue-Tek Optimum cutting temperature (OCT) was purchased from Electron 
Microscopy Sciences (Hatfield, PA). Captisol (CAP) was purchased from Cydex 
Pharmaceuticals Inc. (Lenexa, KS) 
2.2.1. Animals 
Hemizygous MPZ-Raf mice were obtained from Jackson Laboratory (Bar Harbor, 
ME) and bred to homozygosity. Hsp70.1/Hsp70.3 knockout (Hsp70 KO) were originally 
obtained from the Mutant Mouse Resource and Research Center (Davis, CA) and MPZ-
Raf+/+ × Hsp70 KO mice were generated by crossing the strains. The Raf transgene was 
confirmed using the following primers (forward:GCAGCCCACACTGAGGATA; 
reverse:TTGATCGAGTAATCCCCAGCAG,1.1kb). Hsp70 was detected using 
(forward:GTACACTTTAAACTCCCTCC; reverse:CTGCTTCTCTTGTCTTCG, 450bp) 
while the Hsp70 KO was verified using (forward: ATGGGATCGGCCATTGAACAAG 
and  reverse:ACTCGTCAAGAAGGCGATAGAAGG, 850 bp). The reactions contained 
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1x PCR buffer, 0.5 mM dNTPs, 0.5 mM of each primer, 200–300ng genomic DNA and 
0.2U Omni KlenTaq polymerase (DNA Polymerase Technology, St Louis, MO). PCR 
conditions were: (94oC for 5 min; 35 cycles of 94oC for 30s; 65oC for 30s; 72oC for 30s; 
72oC for 5 min). All animals were maintained on a 12h light/dark cycle and given ad 
libitum access to chow (NIH diet 7005) and water.  
Demyelination was induced by intraperitoneal injection of 2 mg of TMX in CO 
on administration schedules that are indicated in the text. A stock solution of 4 mg/ml 
KU-596 in 0.1M Captisol in phosphate-buffered saline (PBS) was prepared and animals 
were dosed by oral gavage (0.2 ml) with the dose and administration schedules indicated 
in the text. Control animals received identical doses of CO and 0.1M Captisol only. All 
animals were randomly assigned to each treatment group and both male and female mice 
were used in all experiments. TMX treated mice showing extensive limb paralysis were 
monitored closely with veterinary supervision, given moistened food directly on the cage 
floor and euthanized if they were unable to access food and water or reached a body 
condition score of 1 (Ullman-Cullere & Foltz 1999).  All procedures complied with 
protocols approved by the Institutional Animal Care and Use Committee and with 
National Institutes of Health standards and regulations for the care and use of laboratory 
rodents. 
2.2.2. Immunoblot analysis 
Sciatic nerves were homogenized and sonicated in lysis buffer containing 50mM 
Tris-HCl, pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 1% deoxycholate, 0.1% SDS, 
0.5 mM sodium orthovandate, 40mM NaF, 10mM β-glycerophosphate and 1X Complete 
Protease Inhibitors. Lysates were centrifuged at 10,000 x g for 10 min at 4oC and protein 
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concentration was determined using the DC (detergent compatible) protein assay (Bio-
Rad Laboratories, Inc.) with bovine serum albumin as the standard. 20µg of protein was 
separated by SDS/PAGE and transferred to nitrocellulose membrane for immunoblot 
analysis. The membranes were blocked for 1h with 5% non-fat milk in PBS with 0.1% 
Tween-20 (PBST) and incubated with primary antibodies overnight at 4oC. Membranes 
were washed 3 times with PBST and incubated with HRP-conjugated goat anti-rabbit or 
goat anti-mouse secondary antibodies for 2h at room temperature. Following 3 washes 
with PBST, immunoreactivity was visualized using enhanced chemiluminescence 
detection kit (GE Healthcare Life Sciences). The films were scanned and the density of 
each blot was analyzed using Image J.  
2.2.3. Immunofluorescence analysis 
Sciatic nerves were harvested from MPZ-Raf mice and immersed in Zamboni’s 
fixative overnight at 4°C. Nerves were washed with PBS and cryoprotected in 30% 
sucrose until the desired dehydration was achieved. Nerves were mounted in OCT and 
cut at 10 µm using a cryostat. Cryosections were collected onto charged slides and stored 
at -80oC until use. Sections were re-hydrated with PBS (3x for 5 min) and permeabilized 
with 0.1% Triton X-100 in PBS for 20 min at room temperature. Tissues were incubated 
overnight at 4oC with primary antibodies diluted in 10% normal goat serum in PBS. 
Sections were washed with PBS and incubated with goat anti-rabbit Alexa Fluor-647 
conjugated secondary antibody for 2h at room temperature. Slides were mounted with 
Diamond prolong antifade with DAPI and imaged on an Olympus/3I Spinning Disk 
Confocal/TRIF Inverted Microscope. 5 random sections were captured using SlideBook 
6.4 (Intelligent Imaging Innovations Inc.). The number of c-jun positive profiles per 
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section was quantified using CellProfiler. Individual nuclei with a diameter of 15-120 
pixels were identified using Otsu’s thresholding method. Identified nuclei with c-jun 
intensity greater than 0.03 were classified as positive.  
2.2.4. Teased Nerve fibers 
Teased nerves were prepared as previously described (Viader et al 2011). Sciatic 
nerves were harvested and fixed with 3% glutaraldehyde overnight at 4°C. Following 3 
washes with 0.1M phosphate buffer, nerves were secondarily fixed with 1% osmium 
tetroxide and 1.5% potassium ferricyanide in 0.5M phosphate buffer for 1 hour. Nerves 
were washed with PBS and incubated with a series of glycerol solutions (33%, 66%, 
100%) for 6h each. Nerves were stained with 0.6% Sudan Black in 70% ethanol for 30 
min, washed with 70% ethanol and water and stored in glycerol. Nerves were teased in 
glycerol on glass slides, allowed to dry and examined under a light microscope.   
2.2.5. Nerve Cross sections 
Sciatic nerves were fixed in 2.5% glutaraldehyde in 0.1M HEPES, pH 7.4 for 24h 
at 4oC. Nerves were then washed with 0.1M HEPES and secondarily fixed with 2% 
osmium tetroxide for 2h. After washing twice with distilled water, nerves were 
dehydrated with a series of 30%, 50%, 70% ethanol solutions for 10 min each. Nerves 
were then rinsed twice with 95% ethanol, 100% ethanol and propylene oxide for 15 min. 
The nerves were placed in a mixture of 50% propylene oxide and 50% resin for 2h, 
transferred into 100% resin and placed in a vacuum chamber overnight. Nerves were 
embedded in flat embedding molds (Ted Pella Inc.) with 100% resin and put in an oven 
overnight at 60oC. 1 µm sections were obtained using a Leica Ultratome system (Leica 
Microsystems Inc.).  Sections were collected onto glass slides and stained with 2% p-
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phenylenediamine in 50% ethanol for 10s on a hot plate at 65°C. Slides were washed, a 
coverslip adhered and examined by light microscopy.  
2.2.6. Behavioral Tests 
Mice were placed on an accelerating rotorod (4-40 rpm) (Med Associate Inc, 
Fairfax, VT) for 5 trials each day with a cutoff of 300s per trial. The latency to fall was 
recorded and the median of the 5 trials was determined. Mice were trained for 5 days 
before the start of a study and were tested every other day.  
As a second assessment of motor function, locomotor activity was quantified with 
high temporal (10 ms) and spatial (2 mm) resolution using a force-plate actometer (FPA) 
(Bioanalytical Systems Inc.) (Fowler et al 2009, McKerchar et al 2006). Mice were 
placed in the FPA chamber for a 10 min session as previously described (Fowler et al 
2001). Data was analyzed using custom-written Free Pascal software and the distance 
traveled in the chamber was calculated. The FPA also measures ambulation rhythmicity 
(stride) and force of paw placement during the strides. The resulting force-time waveform 
reflects the rhythmicity of ambulation while the amplitude of the wave measures the 
force of paw placement during the series of strides. The force data is normalized to body 
weight (%bw) so that variations in amplitude are independent of this variable (Fowler et 
al 2009). Max power and integrated power output were calculated after Fourier 
transformation of the force-time waveform data using a Hanning data window and 
Matlab’s Signal Processing Toolbox.  
2.2.7. Statistical Tests 
Data are presented as means ± standard error of the mean (SEM). After verifying 
equality of variance between groups, parametric data were assessed using a one-way 
 45 
analysis of variance (ANOVA) and Tukey’s post-hoc test. Non-parametric data were 
analyzed using a Kruskal–Wallis and Dunn’s test. A p value < 0.05 was considered 
significant and for clarity, only this value is listed even if the significance was lower. All 
analyses were performed using Systat (v13.1), ProStat (v4.83) or R (v3.4.1) software. 
2.3. Results 
2.3.1. KU-596 decreased TMX-induced c-jun expression 
To investigate the in vivo efficacy of KU-596 to attenuate c-jun-induced 
demyelination, we utilized MPZ-Raf mice. MPZ-Raf mice express a human Raf kinase 
gene fused to a modified estrogen receptor ligand binding domain downstream of the 
myelin protein zero (MPZ) promoter (Napoli et al 2012a). MPZ is expressed specifically 
in SCs and is an important structural component of peripheral nerve myelin. TMX 
administration activates the Raf kinase-fusion protein in myelinated SCs and drives 
downstream activation of the p42/p44 mitogen-activated protein kinase (MAPK) 
pathway, which induces the expression of c-jun. MAPK activation and c-jun induction 
promotes a rapid and robust motor neuropathy characterized by severe demyelination of 
peripheral nerves (Napoli et al 2012a).  
Male and female MPZ-Raf mice were treated with 2 mg TMX dissolved in corn 
oil (CO) every other day for 14 days to induce MAPK activation.  KU-596 (20 mg/kg) or 
vehicle (0.1M Captisol, CAP) was given orally on alternate days starting from day 0 
(Figure 2.3.1.1B). The dose of KU-596 was chosen based on prior studies that 20 mg/kg 
of the drug could improve diabetic peripheral neuropathy. After 14 days, the mice were 
euthanized and immunoblot analysis of sciatic nerve lysates was performed. As expected, 
treating the MPZ-Raf mice with TMX induced the phosphorylation of MAPK (pMAPK) 
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and increased c-jun expression in sciatic nerve (Figure 2.3.1.1C and D). Although KU-
596 treatment did not alter the activation of MAPK, it significantly reduced the level of c-
jun (Figure 2.3.1.1D). Since KU-596 did not decrease pMAPK, the decline in c-jun 
expression is downstream of MAPK activation. Importantly, these results were confirmed 
using cross sections of sciatic nerves stained with antibodies against c-jun and myelin 
basic protein (MBP) (Figure 2.3.1.1E and F). TMX increased the number of c-jun 
positive nuclei and this was significantly attenuated by KU-596. Similarly, TMX also 
decreased MBP immunoreactivity, which was markedly improved by KU-596 treatment. 
No c-jun positive nuclei were noted in animals that received only CO and KU-596. 
  
 47 
Figure 2.3.1.1: KU-596 decreases c-jun expression in TMX treated MPZ-RAF mice. 
A) Structure of KU-596. B) Dosing regimen of MPZ-RAF mice. Mice were treated with Captisol 
(CAP) or KU-596 (20mg/kg) every other day for 14 days starting from Day 0. Beginning on day 
1, mice received corn oil (CO) or 2 mg tamoxifen (TMX) every other day for 14 days. C) Mice 
were sacrificed on day 15, lysates of the sciatic nerves prepared and pMAPK, total MAPK, c-jun 
and β-actin levels determined by immunoblot analysis. D) Quantification of pMAPK (n=3 per 
group) and c-jun expression (CO+CAP, n=9; CO+KU-596, n=8; TMX+CAP, n=15; TMX+KU-
596, n=15). *, p<0.05 compared with CO+CAP. #, p<0.05 compared with TMX+CAP. E) 
Immunostaining of sciatic nerve cross-sections of MPZ-RAF mice. Frozen sections were stained 
for c-jun (green) and MBP (red). F) Frozen sections were stained for c-jun (green) and nuclei 
were visualized with DAPI. The number of c-jun positive nuclei were counted and normalized to 
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the total number of nuclei in two sections obtained from 3 animals per group. *, p<0.05 compared 
with CO+CAP. #, p<0.05 compared with TMX+CAP. Scale bar=20µm. 
 
2.3.2. KU-596 improves demyelination in MPZ-Raf mice 
To determine the effect of KU-596 on myelination profiles, MPZ-RAF mice were 
treated with TMX and KU-596 using the dosing schedule shown in Figure 2.3.1.1B. 
Sciatic nerves were fixed with osmium tetroxide, teased in glycerol and examined under a 
light microscope. Whereas control mice (CO+CAP, CO+KU-596) showed normal 
myelination with well demarcated nodes of Ranvier, nerves from TMX+CAP treated 
mice showed large regions denuded of myelin (Figure 2.3.2.1A). Although KU-596 
trended toward reducing the length of the demyelinated region, the effect was variable 
(Figure 2.3.2.1B). To further quantify the effect, a teased fiber was considered damaged 
if the distance between two myelinated sections was at least 10% greater than the average 
distance between internodes of CO+CAP treated animals (Figure 2.3.2.1B).  By this 
criterion, the drug significantly decreased the percentage of damaged fibers (Figure 
2.3.2.1C). In addition, cross sections of sciatic nerves indicated an increased number of 
abnormally myelinated fibers in the TMX+CAP group (Figure 2.3.2.2A). KU-596 
treatment reduced by 25% the number of abnormally myelinated fibers defined as those 
with a myelin sheath, exhibiting myelin splitting, having myelin debris, onion bulbs, 
myelin ovoids or presence of regeneration clusters (Figure 2.3.2.2B). Despite the rapid 
onset and robust level of demyelination induced by TMX, these data suggest that KU-596 




Figure 2.3.2.1: KU-596 improves myelin integrity. 
A) Representative pictures of the effect of TMX and KU-596 treatment on myelination in teased 
sciatic nerves of MPZ-RAF mice (scale bar= 10µm). B) Quantification of the demyelinated 
length of sciatic nerves in TMX and TMX+KU-596 treated MPZ-Raf mice. Columns represent 
individual animals and dots represent length of demyelinated regions in individual teased nerves.  
Bar indicates median. C) Quantification of percentage of damaged nerves in each group. Nerves 
with demyelinated distances that were at least 10% greater than the average distance between two 
internodes in the CO+CAP treated MPZ-RAF mice were classified as damaged. *, p<0.05 











































Figure 2.3.2.2: KU-596 decreased abnormally myelinated fibers.  
A) Cross section of sciatic nerves of MPZ-RAF mice. Examples of myelin splitting (arrows) and 
demyelinated fibers (arrowheads) are indicated. Scale bar, 10µm. B) Quantification of 
abnormally myelinated nerves in each group. Abnormal myelination was defined as the presence 
of myelin splitting, myelin debris, onion bulbs, myelin ovoids and regeneration clusters. Each 
symbol represents the average from one section that was counted twice in separate sessions while 
blinded to treatment. The number of animals per group was CO+CAP (n=4), CO+KU-596 (n=3), 
TMX+CO (n=6) and TMX+KU-596 (n=5). Kruskal–Wallis non-parametric test, *, p<0.05 

































2.3.3. KU-596 improves motor function in MPZ-Raf mice  
Since demyelination mainly affects large caliber motor nerves, we sought to test 
the effects of TMX and KU-596 on motor function by examining the ability of the mice 
to stay on a ramping rotorod. Animals were randomly assigned to each of the 4 treatment 
groups and given 5 training trials on the rotorod. MPZ-RAF mice were treated using an 
alternate day dosing schedule with day 0 serving as the baseline rotorod performance 
prior to any treatment. Animals were given 20 mg/kg KU-596 on alternate days 
beginning at day 0, while TMX was administered every other day beginning at day 1.  
As expected (Napoli et al 2012a), TMX+CAP treated mice developed an impaired 
motor coordination and showed a sharp decrease in the latency to fall beginning at day 10 
(after 4 TMX doses) (Figure 2.3.3.1A and B). Compared to mice treated with TMX+CAP 
mice, animals that received TMX+KU-596 showed a significantly delayed onset of the 
motor deficit and a preservation of motor function. Indeed, TMX+CAP mice showed an 
abnormal posture and rear limb positioning with the most severe mice exhibiting 
paraparesis (Figure 2.3.3.1C, top). In contrast, TMX+KU-596 treated mice had a 
relatively normal posture (Figure 2.3.3.1C, bottom), the limbs were able to support the 
body weight and the mice more effectively used all four limbs when ambulating, as 
discussed below.  
  
 52 
Figure 2.3.3.1: KU-596 improves motor function of TMX treated MPZ-RAF mice. 
A) Latency to fall on the rotorod was assessed in 5 trials and the median was recorded. KU-596 
increased time on the rotorod indicating improved motor function (n = 8-13). *, p<0.05 compared 
with CO+CAP. #, p<0.05 compared with TMX+CAP. B) Latency to fall of individual mice from 
each group on Days 10, 12, and 14, respectively. C) Representative pictures of MPZ-Raf mice 
treated with TMX+CAP (top) or TMX+KU-596 (bottom) at the end of the study. D) Mice were 
placed in the FPA for 10 min and the distance traveled (Di) and paw placement forces (Diii) were 
recorded. Numerical data for distance traveled in meters are shown in the lower margin of Di for 
the three groups. The second row of panels (Dii) represents the corresponding Fourier transforms 
of the force-time waveforms shown in Diii. Together Dii and Diii establish the rhythmic character 
and power output of individual bursts of locomotion. The fourth row of panels (Div) show 
enlarged images of force-time waveforms for the indicated animal in each group to more clearly 
illustrate treatment-related differences in ambulation power and rhythmicity. *, p < 0.05 versus 
CO+CAP; # p< 0.05 vs TMX+CAP. 
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Since the rotorod test is a rather gross indication of motor coordination, we 
employed a force plate actometer (FPA) to quantify locomotor activity with high 
temporal (10 ms) and spatial (2 mm) resolution (Fowler et al 2009, McKerchar et al 
2006). No training of the animal is required since the FPA measures multiple movement 
parameters as the mouse freely explores the FPA chamber during a 10 min session. 
Animals were treated with TMX and KU-596 as discussed above and motor function in 
the FPA was assessed on day 14. Figure 2.3.3.1Di shows representative patterns of 
movement and overall distance traveled by the mice in the FPA chamber. Compared to 
control mice, TMX treated mice tended to restrict their movement around the perimeter 
of the chamber and showed a significant decrease in the total distance traveled from 25.4 
meters to 6.7 meters. This is likely due to the extensive paraparesis (Figure 2.3.3.1C) and 
not a behavioral deficit induced by TMX; WT mice treated with TMX showed normal 
exploratory behavior (data not shown). In contrast, the overall distance traveled by mice 
receiving TMX+ KU-596 was significantly increased compared to the TMX + CAP 
group, and approximated the exploratory behavior of the control mice, though it remained 
slightly decreased.  
The FPA also measures ambulation rhythmicity (stride) and force of paw 
placement during the strides. The panels in Figure 2.3.3.1Diii show representative force-
time waveforms of paw placement forces during a straight run in the FPA. The symmetry 
of the force-time peaks represents the rhythmicity of ambulation during the series of 
strides while the amplitude of the wave measures the force of paw placement (power 
output). To quantify power output, it is normalized to body weight (%bw) so that 
variations in amplitude are independent of this variable (Fowler et al 2009). TMX 
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treatment clearly abolished the peak symmetry (rhythmicity of the stride) and peak 
amplitude (force of the paw hitting the force plate). The panels in Figure 2.3.3.1Div are a 
magnified view of the force data from one animal per group to highlight the differences 
in movement. These deficits result from the loss of limb coordination (Figure 2.3.3.1C) 
and inability of the limbs to sustain the body weight.  Changes in force can be quantified 
following Fourier transformation of the waveforms which produces a power spectra 
(Figure 2.3.3.1Dii). The peak around 8-9 Hz in control mice represents normal 
ambulation rhythmicity and integration of the area under the curve (AUC) provides an 
indication of the force. TMX clearly abolished rhythmicity and significantly decreased 
the AUC in the power spectra. However, mice treated with KU-596 showed a significant 
improvement in ambulation rhythmicity and force. Together, these data indicate that 
decreased c-jun expression and the improved myelination following KU-596 treatment 
correlated with the development of a less severe motor neuropathy.  
2.3.4. KU-596 improves a pre-existing motor deficit in MPZ-Raf mice 
To test the ability of KU-596 to reverse a pre-existing motor deficit, rotorod 
performance was assessed every other day for 9 days in a group of 42 MPZ-Raf mice. 
After each session, the mice were administered TMX every other day for a total of 5 
doses over the 9 days (Figure 2.3.4.1A). By day 11, the latency to fall was approximately 
< 75% of the baseline on day 1. After assessing the rotorod latency on day 11, the mice 
were randomly assigned to one of four groups which received daily doses of 0 (n=12), 
0.1, 1 or 10 mg/kg of KU-596 (n=10 each) from days 11 to day 18. This log range was 
chosen since 0.1 mg/kg shows minimal efficacy in improving diabetic peripheral 
neuropathy. Performance on the rotorod was assessed every other day from days 13 - 19 
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(Figure 2.3.4.1B). The latency to fall in mice receiving 0.1 mg/kg of KU-596 remained 
significantly impaired compared to the control mice and was indistinguishable from the 
mice treated with TMX + CAP. Mice receiving 1 or 10 mg/kg KU-596 did show some 
improvement in the latency to fall since they were not significantly different from the CO 
control group at days 13, 15 and 19. However, the magnitude of this improvement was 
not sufficient to be statistically different relative to the TMX + CAP group at any of the 
time points. Analysis of the latency to fall responses of individual animals indicated a 
rather wide variability among those treated with either TMX + CAP or TMX + KU-596 
(data not shown). Therefore, to minimize the effect of animals that were either poor or 
good responders, the median fall latency in each group at each time was used to 
determine if the drug was having a significant effect over the duration of treatment. The 
median fall latencies for each treatment at days 13 – 19 were combined (4 time points per 
group) and analyzed by one-way ANOVA and Scheffe’s post-hoc test (Figure 2.3.4.1C). 
This analysis suggests that daily dosing with 1 and 10 mg/kg KU-596 from days 11-18 
significantly increased the fall latency over this treatment period.   
  
 56 
Figure 2.3.4.1: KU-596 improves a pre-existing motor deficit.  
A) TMX was given every other day until the latency to fall dropped to about 75% of baseline by 
day 11. After the rotorod session on day 11, animals were randomly assigned to be treated daily 
with 0 – 10 mg/kg KU-596 and the dosing was initiated.  B) Latency to fall of MPZ-RAF mice on 
the rotorod. Each mouse received 5 trials and the median of latency to fall was recorded. The 
arrow points to the start of daily KU-596 or vehicle treatment. TMX produced a statistically 
significant decrease in response latency that was not improved by 0.1 mg KU-596. *, p<0.05 
compared with CO+CAP. Though the response latency in mice treated with 1 or 10 mg/kg KU-
596 was not significantly different from the control group, it was significantly improved from 
animals that only received Captisol.  C) The median of each treatment at days 13-19 were 
grouped and analyzed to minimize variability associated with good versus poor responders. One 
way ANOVA and Scheffe’s post-hoc test indicated that 1 and 10 mg/kg KU-596 improved motor 





































































2.3.5. Hsp70 is required for drug efficacy 
Our previous work indicated that the ability of KU-596 to improve sensory 
deficits associated with the development of DPN is Hsp70-dependent (Li et al 2012b, Ma 
et al 2014, Ma et al 2015, Urban et al 2010). However, demyelination is not a hallmark of 
the sensory neuropathy that develops in diabetic rodents. Therefore, to determine if the 
ability of KU-596 to improve the demyelinating motor neuropathy in MPZ-Raf mice is 
also Hsp70-dependent, MPZ-Raf × Hsp70 KO mice were generated (Figure 2.3.5.1A). 
Importantly, deletion of Hsp70 had no effect in altering the expression of the constitutive 
isoform, Hsc70, in sciatic nerve.  
Deletion of Hsp70 did not affect basal motor coordination since untreated MPZ-
Raf × Hsp70 KO mice (Figure 2.3.5.1B) performed as well as the MPZ-Raf mice (Figure 
2.3.3.1A and B) on the rotorod. As described for Figure 2.3.1.1A, MPZ-Raf x Hsp70 KO 
mice were also given 20 mg/kg KU-596 on alternate days beginning at day 0, while TMX 
was administered every other day beginning at day 1. Treating the MPZ-Raf × Hsp70 KO 
mice with TMX induced a progressive decrease in the latency to fall from the rotorod 
indicating that Hsp70 is not necessary to develop the motor neuropathy. However, in 
contrast to the MPZ-Raf mice, 20 mg/kg of KU-596 was unable to improve rotorod 
performance (Figure 2.3.5.1B). Consistent with this result, KU-596 also did not improve 
the distance traveled in the FPA (Figure 2.3.5.1Ci and D) nor ambulation rhythmicity 
(Figure 2.3.5.1Cii). Lastly, although TMX increased c-jun levels in sciatic nerve (Figure 
2.3.5.1E), KU-596 was unable to decrease c-jun as occurred in the MPZ-Raf mice. These 
data indicate that KU-596 requires Hsp70 to improve the motor neuropathy and link 
Hsp70 to the decrease in c-jun.   
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Figure 2.3.5.1: KU-596 improves the motor deficit in an Hsp70 dependent manner. 
 
A) The left panel shows genotype analysis of the MPZ-Raf x Hsp70 KO mice. A- Raf transgene; 
B, Hsp70 WT; C, Hsp70 KO. The animal in white font was heterozygous for the Hsp70 KO while 
the animal in red font was homozygous. The right panel shows immunoblot analysis of sciatic 
nerve from 2 C57Bl/6 mice and four MPZ-Raf x Hsp70 KO mice. The mice lacked Hsp70 
expression and this had no effect on altering the expression of Hsc 70.  B) Mice were given 20 
mg/kg KU-596 on alternate days beginning at day 0, while TMX was administered every other 
day beginning at day 1. Mice were trained for 5 days on the accelerating rotorod and tested every 
other day. Each mouse received 5 trials and the median latency to fall was recorded. KU-596 
treatment showed no effect on the latency to fall compared with the TMX+CAP group. C) Mice 
were treated with TMX and KU-596 as described above and on day 15, and the total distance 
traveled (Ci) was quantified (D). (E) Sciatic nerves were analyzed for c-jun expression by 





c-Jun belongs to the AP-1 transcription factor family and was first discovered as an 
oncogene (Yamanishi et al 1991).  Although elevated c-jun is not the cause of all 
neuropathies, it may be an important culprit. Parkinson et al. were the first to demonstrate 
that c-jun is a negative regulator of myelination and is required for SC dedifferentiation 
(Parkinson et al 2008). Our data suggests that decreasing c-jun expression with KU-596 
therapy correlates with a decrease in demyelination and improved motor function in 
MPZ-Raf mice, a robust model of a rapid onset demyelinating neuropathy. Moreover, 
drug efficacy seems to require Hsp70 as improved motor function could not be 
recapitulated in MPZ-Raf x Hsp70 KO mice.  
Hsp70 is mechanistically known to inhibit the JNK pathway and protect neurons 
from apoptosis (Bienemann et al 2008, Lee et al 2005). However, the phosphorylation of 
c-jun by JNK is not necessary for c-jun to promote demyelination(Parkinson et al 2008). 
Our published work using an earlier generation C-terminal Hsp90 inhibitor, KU-32, 
indicated that an increase in the proteasomal clearance of c-jun and phospho-c-jun was 
linked to protecting against demyelination in SC-sensory neuron co-cultures (Li et al 
2012b). Thus, we anticipate that the decrease of c-jun expression is more likely due to 
increased clearance rather than decreased production, but this remains to be demonstrated 
in vivo. One possible mechanism for enhancing c-jun clearance via Hsp70 is through the 
carboxy terminus of heat shock cognate protein 70 (Hsc70) interacting protein (CHIP). 
CHIP is an Hsp70 interacting E3 ubiquitin ligase that mediates the proteasomal clearance 
of Hsp70 substrates by binding to a C-terminal EEVD sequence of the chaperone (Dickey 
et al 2007b). Since Hsp70 can co-immunoprecipitate c-jun, an Hsp70-CHIP complex may 
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be involved its clearance. However, no reports have linked CHIP as a critical mediator 
for c-jun degradation. On the other hand, the F-box protein, Fbw7, is known to enhance 
the clearance of c-jun by promoting its ubiquitination by the SCF ubiquitin E3 ligase 
complex (Hoeck et al 2010, Wang et al 2011). Phosphorylation of c-jun at T239 and S243 is 
required for its recognition by Fbw7 (Wei et al 2005) and TMX-treated mice showed an 
increase in c-jun phosphorylation at these residues (data not shown).  Fbw7 is readily 
detected in sciatic nerve extracts and can also co-immunoprecipitate with Hsp70 from 
cell extracts (data not shown). Little is known about how c-jun is cleared in SC and these 
observations suggest that Fbw7 may regulate c-jun function. The role of Fbw7 in 
regulating c-jun clearance via KU-596 and Hsp70 is currently being examined using mice 
with a SC-specific conditional deletion of Fbw7.  
Although KU-596 therapy could not decrease c-jun levels in the absence of 
Hsp70, it remains unclear if a decrease in c-jun is critical to mediating the improvement 
in nerve function or is a consequence of other mechanisms by which Hsp70 may 
ameliorate the neuropathy, i.e., enhancing mitochondrial bioenergetics or decreasing 
inflammation (Ma et al 2015).  Moreover, emerging data suggests that c-jun serves a 
complicated role in SC function. In response to injury or metabolic insults, robust 
induction of c-jun in myelinated adult SCs is recognized as essential for promoting 
dedifferentiation of the myelinated phenotype (Parkinson et al 2008). For instance, an 
increase in SC c-jun expression correlates with the extensive demyelination that occurs in 
a mouse model of human CMT1X (Klein et al 2014). Though high levels of c-jun 
expression are sufficient to drive SC dedifferentiation, c-jun levels decline after loss of 
the myelin membrane. Recent data supports that a low level of c-jun expression in 
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injured SCs may be important to produce trophic factors, such as glial derived 
neurotrophic factor, that can aid the survival of the desheathed sensory neurons 
(Arthur-Farraj et al 2012, Fontana et al 2012b).  For example, the C3 mouse model of 
CMT1A shows a decrease in the number of myelinated sensory axons compared to wild 
type mice (Hantke et al 2014). However, SC-specific deletion of c-jun in the C3 mouse 
exacerbated the loss of myelinated sensory axons, suggesting a supportive role of c-jun in 
axonal survival (Hantke et al 2014). While pharmacologic modulation of c-jun levels is 
distinctly different from its genetic deletion, it is translationally important to determine if 
the drug may interfere with, complement or supplant any trophic actions of c-jun in 
supporting desheathed axons in relevant disease models that have a SC-specific deletion 
of c-jun.  
A second caveat of our work is that the rapid onset demyelinating neuropathy 
shown by the MPZ-Raf mice does not mimic a human disease. Importantly, c-jun is 
elevated in several inherited neuropathies, such as CMT1A, CMT1B, and CMT1X 
(Hutton et al 2011, Klein et al 2014). The ability of KU-596 to improve motor function in 
this rapid and robust model of a demyelinating neuropathy suggest it may have clinical 
potential in these slower onset diseases since muscle weakness and limited mobility are 
major complaints from afflicted patients (Johnson et al 2014, Kelly et al 2015). Since 
induction of Hsp70 by N-terminal Hsp90 inhibitors can clear protein aggregates in 
models of CMT1A (Chittoor et al 2013, Rangaraju et al 2008a), KU-596 may be 
beneficial in treating this inherited neuropathy since it has a broader therapeutic window 
that promotes Hsp70 induction without increasing client protein degradation, which 
would be neurotoxic. The application of KU-596 in treating CMT1X would be intriguing 
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as well. Since CMT1X is a mixed axonal and demyelinating neuropathy, decreasing c-jun 
expression may help improve aspects of the demyelinating neuropathy while providing 
some support for the axonal neuropathy via its documented ability to improve at least 
sensory neuron mitochondrial bioenergetics.  Furthermore, a SC-dependent secondary 
inflammation that stimulates macrophage-mediated demyelination contributes to the 
progressive neuropathy in CMT1X (Groh et al 2010, Groh et al 2015). C-C motif 
chemokine (CCL2) is derived from SCs, and attracts macrophages to infiltrate the 
endoneurium and directly contribute to myelin degeneration in CMT1X (Martini & 
Willison 2015). Since c-jun can transcriptionally increase CCL2 (Wolter et al 2008), 
decreasing its levels may abrogate CCL2 production and decrease macrophage-
mediated myelin degeneration in CMT1X. Consistent with this premise, transcriptomic 
analysis found that KU-596 therapy broadly decreased the expression of inflammatory 
genes and was predicted to decrease CCL2 activation in diabetic dorsal root ganglia 
(Ma et al 2015). The potential utility of KU-596 and Hsp70 in improving physiologic 
read outs of nerve function in mouse models of CMT1X is currently being assessed.  
In summary, we show that novologue therapy can attenuate the severe 
morphologic and physiologic indices of a demyelinating neuropathy that rapidly 
occurs in the MPZ-Raf mice. Since human demyelinating neuropathies typically show 
a more gradual development, this bodes well for the drug’s translational potential. 
Combined with our extensive published data on the efficacy of novologues in 
attenuating a metabolic neuropathy (Ma et al 2014, Ma et al 2015, Urban et al 2010, 
Urban et al 2012), these data provide strong proof-of-principle that the upregulation of 
endogenous cytoprotective pathways can attenuate neuropathies of distinct etiologies.   
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Chapter 3. Modulating Molecular Chaperones Improves Demyelinating 
Neuropathy in a Mouse Model of Charcot-Marie-Tooth 1X 
Abstract 
X-linked Charcot-Marie-Tooth (CMT1X) disease is the second most common 
form of CMT and is caused by mutations of the gap junction beta-1 gene (GJB1) which 
encodes the protein connexin 32 (Cx32). The loss of function of Cx32 accounts for the 
symptoms of CMT1X due to the development of a mixed axonal and demyelinating 
neuropathy. Cx32 deficient mice (Cx32def) are an accepted model of human CMT1X 
and are useful for evaluating novel pharmacologic approaches to treat CMT1X, which are 
desperately needed by patients. “Novologues” are orally bioavailable, non-toxic small 
molecules that improve metabolic and clinical indices of diabetic peripheral neuropathy 
by modulating the expression of the molecular chaperone heat shock protein 70 (Hsp70). 
We have also identified that novologue therapy has promising efficacy in improving 
neuromuscular function in the Cx32def animal model of CMT1X. Recent evidence 
suggests that c-jun could be a potential target for treating CMT1X since elevated levels of 
c-jun can promote demyelination. Young Cx32def mice exhibit an early axonopathy and 
treating 3-month-old Cx32def mice for 1 month with the novologue, KU-596, dose 
dependently decreased c-jun expression in Schwann cells of the femoral nerves and 
improved motor nerve conduction velocity (MNCV) and compound muscle action 
potential (CMAP). Older Cx32def mice develop a demyelinating neuropathy and treating 
6-month-old Cx32def mice for 3 months with KU-596 improved grip strength and 
MNCV. The therapeutic effects of KU-596 depend on Hsp70 since grip strength and 
MNCV were not improved by 3 months of drug therapy in Cx32def x Hsp70 knockout 
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mice. Collectively, our data indicate that modulating Hsp70 could be beneficial in 
treating CMT1X possibly due to effects on decreasing the expression of c-jun. Since 
novologues are entering Phase 2 trials, this therapy shows promise as a rapidly 




X-linked Charcot-Marie-Tooth disease (CMT1X) is caused by mutations in the 
gap junction beta 1 (GJB1) gene (Gal, Mucke et al. 1985). Over 400 mutations of the 
GJB1 gene have been reported to be associated with CMT1X (Kleopa et al 2012, 
Panosyan et al 2017). CMT1X is the second most common type of CMT, accounting for 
nearly 20% of CMT1 cases (Braathen 2012). Because CMT1X is an X-linked dominant 
disorder, males have an earlier onset, usually within the first two decades of life, and are 
more severely affected than female patients. CMT1X patients present classic 
neuromuscular symptoms including foot drop, steppage gait, and pes cavus. Symptoms 
first appear in the distal foot and leg muscles and gradually progress to the upper limbs 
(Shy, Siskind et al. 2007).  
The GJB1 gene encodes the gap junction protein connexin 32 (Cx32) that is found 
at the Schmidt-Lantermann incisures and within non-compact myelin (Scherer et al 
1995). Cx32 contains cytoplasmic amino and carboxy termini, four transmembrane 
domains, and one intra- and two extra-cellular loops. Hexamers of Cx32 form a 
hemichannel and in the peripheral nervous system (PNS), gap junction channels are 
formed by hemichannels that contain only Cx32 (Kleopa & Sargiannidou 2015). The 
Cx32 gap junction channels allow molecules less than 1 kDa to pass through the SC 
cytoplasm with a thousand-fold shorter distance than the circumferential pathway 
(Balice-Gordon et al 1998, Scherer et al 1995). The loss of function of Cx32 solely 
accounts for the peripheral symptoms in CMT1X and Cx32 deficient (Cx32def) mice 
mimic many features of the peripheral neuropathy that develop in humans. Thus, 
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Cx32def mice provide an excellent animal model for assessing mechanisms of disease 
development and exploring the efficacy of potential therapeutics.  
Though the mechanism by which a loss-of-function of Cx32 leads to the 
neuropathic phenotype is unknown, Cx32def mice clearly exhibit a two-stage neuropathy. 
In contrast to the initial discovery, where no neurological changes were observed at 3 
months of age (Nelles et al 1996), Vavlitou et al found that axonal damage started to 
occur at 2 months of age, prior to demyelination (Vavlitou et al 2010). This first stage of 
axonopathy is associated with an increase in the transcription factor c-jun, a decrease in 
phosphorylated neurofilament, and a decrease in axon diameter (Klein et al 2014). The 
second stage is a macrophage-mediated demyelinating neuropathy that evolves around 
6 months of age. It is hypothesized that the mutant SCs send an unidentified signal to 
fibroblasts, which then secrete colony stimulating factor-1 (CSF-1) that activates the 
macrophage-mediated neurodegeneration (Groh et al 2016, Groh et al 2015, Martini & 
Willison 2016). Mutant SCs also secrete C-C motif chemokine (CCL2) that guides 
macrophages to mutant SCs (Kohl et al 2010). This stage of the neuropathy is 
associated with a robust increase in c-jun expression (Klein et al 2014), which can 
induce the transcription of CCL2 (Wolter et al 2008). Since c-jun drives SC 
dedifferentiation (Jessen & Mirsky 2016) and promotes macrophage-mediated damage, 
attenuating the expression of c-jun may serve as a valid therapeutic strategy. To this 
end, we propose using an innovative small molecule chaperone modulator to 
pharmacologically manage CMT1X. 
Molecular chaperones such as Hsp70 and Hsp90 play important roles in protein 
folding, assembly, regulation and degradation. They also act as the first-line of defense 
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against stress (Feder & Hofmann 1999). Recent evidence suggests that modulating 
Hsp70 yields promising neuroprotective effects in neurodegenerative diseases 
associated with protein aggregation, such as Alzheimer’s disease (AD) and 
Parkinson’s disease (PD)(Dickey et al 2006, Dickey et al 2007a, Luo et al 2007a, 
Putcha et al 2010). However, the use of small molecules directly targeting Hsp70 has 
been shown to be challenging (Assimon et al 2013). Alternatively, Hsp70 expression 
could be regulated indirectly through the modulation of Hsp90 to induce an HSR. The 
binding of Hsp90 inhibitors to Hsp90 disrupts the Hsp90-HSF1 complex and releases 
HSF1. Following phosphorylation and trimerization, the released HSF1 binds to the 
HSE and induces the transcription of Hsps, especially Hsp70 (Neef et al 2011).  
N-terminal Hsp90 inhibitors have been shown to reduce toxic aggregates in 
neurodegenerative diseases, such as AD and PD (Luo et al 2007a, Putcha et al 2010). 
However, many N-terminal inhibitors have limited application since they induce 
degradation of normal client proteins in addition to the induction of HSR. We 
developed a series of novobiocin-based small molecule C-terminal Hsp90 inhibitors, 
termed novologues, which induce the HSR at a much lower concentration than the 
concentration needed to induce client protein degradation. The second-generation 
novologue, KU-32, has been shown to protect neurons from amyloid-β induced 
toxicity (Ansar et al 2007). Moreover, in mouse models of diabetic peripheral 
neuropathy (DPN), weekly treatment of KU-32 improved mitochondrial bioenergetics 
and reversed sensory deficits (Ma et al 2014). Importantly, KU-32 was also found to 
attenuate demyelination by regulating c-jun expression. Using myelinated SC-dorsal 
root ganglia co-cultures, c-jun induction and demyelination can be rapidly induced by 
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the addition of neuregulin 1 Type 1. Treating the myelinated co-cultures with KU-32 
prior to inducing demyelination with neuregulin 1 decreased c-jun expression, and 
blocked the extensive demyelination. Mechanistically, this neuroprotection required 
Hsp70 since the drug could not prevent neuregulin-induced demyelination in co-
cultures prepared from Hsp70 KO mice (Li et al 2012a).  
Although KU-32 is a potent neuroprotective C-terminal Hsp90 inhibitor, 
further structure activity studies identified KU-596 as a next generation novologue 
with a more facile synthesis that protected sensory neurons with an improved ED50 
(Kusuma et al 2012a). Like KU-32, KU-596 improved mitochondrial bioenergetics 
and sensory deficits in a mouse model of DPN in an Hsp70-dependent manner (Ma et 
al 2015). As discussed in Chapter 2, oral administration of KU-596 reduced c-jun 
expression, the extent of demyelination and improved motor function in a transgenic 
model of a demyelinating neuropathy. To more fully evaluate the potential of KU-596 
to improve a neuropathy that models a human disease, we used Cx32def mice to 
explore whether KU-596 may be beneficial in the context of CMT1X. Our data 
suggests that modulating molecular chaperones could provide a new therapeutic 
strategy towards the treatment of CMT1X. 
3.2. Materials and Methods 
3.2.1. Materials 
KU-596, N-(2-(5-(((3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetrahydro-
2H-pyran-2-yl)oxy)-3'-fluoro-[1,1'-bi- phenyl]-2-yl)ethyl)-acetamide was synthesized as 
previously described (Kusuma et al 2012a). Compound purity routinely exceeded 95%. 
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Captisol (CAP) was purchased from Cydex Pharmaceuticals Inc. (Lenexa, KS) and was 
used to solubilize KU-596 for oral administration and served as the drug vehicle.  
c-Jun antibody was purchased from Cell Signaling Technology (#9165, Danvers, 
MA). The specificity of the antibody was demonstrated using nerves isolated from 
animals in which c-jun was conditionally deleted in Schwann cells (data not shown). 
Goat anti-mouse-HRP and goat anti-rabbit-HRP were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). β-actin antibody was purchased from MP Biomedical 
(Santa Ana, CA). Goat anti-rabbit Alexa Fluor-647, Diamond prolong antifade mounting 
solution with 4', 6-diamidino-2-phenylindole (DAPI) and 10% normal goat serum (NGS) 
in phosphate buffered saline (PBS) was purchased from Life technologies (Calrsbad, 
CA). Tissue-Tek Optimum cutting temperature (OCT) was purchased from Electron 
Microscopy Sciences (Hatfield, PA). 
3.2.2. Animals 
Thanks to Dr. Rudolf Martini for his generous gift of Cx32 deficient (Cx32 def) 
mice (Nelles et al 1996). Cx32 def x Hsp70 KO mice were generated by crossing Cx32 
def mice with Hsp70.1/Hsp70.3 knockout (Hsp70 KO) mice (Mutant Mouse Resource 
and Research Center (Davis, CA)). C57Bl/6 mice were used as wild type (WT) controls. 
Genotypes were confirmed using the primers listed in Table 3.2.1.1. All animals were 
maintained on a 12h light/dark cycle and given ad libitum access to water and chow (NIH 
diet 7005). 
Table 3.2.1.1: Primers for genotyping 
Gene Primer Band size 
















3.2.3. Immunoblot Analysis 
Sciatic nerves were collected and homogenized in lysis buffer (50mM Tris-HCl, pH 
7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 1% deoxycholate, 0.1% SDS, 0.5 mM 
sodium orthovandate, 40mM NaF, 10mM β-glycerophosphate and 1X Complete Protease 
Inhibitors). After centrifuging at 10,000 x g for 10 min at 4°C, protein concentration of 
lysates was determined using DC (detergent compatible) protein assay (Bio-Rad 
Laboratories, Inc.). 20 µg of protein were separated by SDS-PAGE and transferred to a 
nitrocellulose membrane. Membrane was blocked with 5% non-fat milk in phosphate 
buffered saline (PBS) containing 0.1% Tween-20 (PBST) and incubated with primary 
antibody overnight at 4°C. On the next day, the membrane was washed and followed by 
incubation with HRP-conjugated secondary antibody. After 2h, the membrane was 
washed and the immunoreactivity was detected using enhanced chemiluminescence 
detection kit (GE Healthcare Life Sciences). The films were scanned and Image J is used 
to analyze the density of the blot. 
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3.2.4. Immunofluorescence Analysis 
Motor branch of femoral nerves were collected and immersion fixed in Zamboni's 
fixative overnight at 4°C. After washing three times with PBS, nerves were cryoprotected 
with 30% sucrose until the tissue sinked in the solution. Nerves were embedded in OCT 
and cut at 10 µm using a cryostat. Sections were first re-hydrated with PBS three times 
for 5 min each cycle followed by permeabilization with 0.1%Triton X-100 in PBS for 20 
min. After blocking with 0.3% Triton X-100 in 10% normal goat serum (NGS, Life 
technologies, Calrsbad, CA) for 1h, tissues were placed at 4°C and incubated with 
primary antibodies diluted in 10% NGS in PBS overnight. Sections were washed with 
PBS and incubated with conjugated goat anti-rabbit-Alexa Fluor-647 for 2h in dark. 
Slides were mounted with Diamond prolong antifade with DAPI and imaged on an 
Olympus/3I Spinning Disk Confocal/TRIF Inverted Microscope. 3-5 random sections 
were captured using SlideBook 6.4 (Intelligent Imaging Innovations Inc.) for each 
animal. Images were quantified using CellProfiler software. The percentage of c-jun 
positive nucleus was calculated by dividing the number of positive nucleus by the 
number of total nucleus (3-5 sections per animal). 
3.2.5. Behavioral Tests 
For the grip strength test, mice were placed parallel on the grid. After the 
hindpaws attached to the grid, the mouse was horizontally and steadily pulled back until 
their grip was released. The average of eight readings was used. High-resolution force 
plate actometer (FPA) (Bioanalytical Systems Inc.) was used to assess the paw placement 
force of the mice. Mice were placed on the FPA for a 10 min session every week. The 
FPA measures the force of paw placement during strides and present it as a force-time 
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waveform normalized to bodyweight (%bw) (Fowler et al 2009, McKerchar et al 2006). 
The amplitude of the wave represents the force of paw placement. Max power was 
calculated after Fourier transformation of the force-time waveform data using a Hanning 
data window from Matlab’s Signal Processing Toolbox. 
3.2.6. Electrophysiological measurements 
At the end of the study, mice were anesthetized with mixed solution of ketamine and 
xylazine. MNCV, SNCV (McGuire et al 2009) and CMAP (Ruiz et al 2005, Simon et al 
2010) were measured as previously described.  
3.2.7. Luciferase activity assay 
50B11 cells were transfected with a dual reporter plasmid that expressed secreted 
alkaline phosphatase (SEAP) under a CMV promoter and Gaussia luciferase driven by a 
1.5 kb region of the CCL2 promoter that contains two c-jun recognition elements. 
Following transfection, the cells were treated with DMSO or 1µM KU-596 and were 
serum deprived overnight to render them quiescent. The following day, the cells were 
stimulated for 2h by the addition of 10% serum. The medium was collected and cell 
lysates were collected for western blot. Luciferase and SEAP activity were measured 
using a secrete-pair dual luminescence assay kit (GeneCopeia). Luminescence was 
measured by a plate reader at 480 nm. Data were represented as relative luminescence 
unit (RLU), which is the ratio of luciferase to SEAP. Control cells remained in complete 
medium (DMEM, 10% FBS, 1% penicillin and streptomycin) the whole time and were 
either transfected with CCL2 plasmid or left untransfected. After overnight treatment 
with either vehicle or 1µM KU-596, cells and media were collected for luciferase assay 
and immunoblot analysis. 
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3.2.8. Statistical Tests 
All data points shown are presented as means ± standard errors of the mean 
(SEM). Datasets were first tested for normality using the Shapiro-Wilk test. Groups with 
equal variances are subjected to one-way analysis of variance (ANOVA) and Tukey's 
post-hoc test for statistical analysis. Student's t-test was used when comparing two 
groups. Results are considered significant when p<0.05. Krusal-Wallis and Dunn's test 
were used for non-parametric data sets. All statistical analyses were performed using R 
(v3.4.1) software. 
3.3. Results 
3.3.1. KU-596 treatment decreased c-jun expression in young Cx32 def mice 
We utilized Cx32def mice to model human CMT1X. We started to test our 
hypothesis in 3-month-old Cx32def mice. At this stage, axonopathy has already occurred 
and an increased level of c-jun has been reported, but demyelination does not start to 
occur until after 4 months of age (Klein et al 2014, Vavlitou et al 2010). To test whether 
KU-596 could decrease c-jun expression, we performed a dose-response experiment by 
treating Cx32def mice with 0.3mg/kg, 1mg/kg, or 3mg/kg of KU-596 daily for one month 
and examined the expression level of c-jun in sciatic nerve extracts. After a month of 
treatment, KU-596 dose-dependently decreased c-jun expression in the sciatic nerve of 
Cx32def mice (Figure 3.3.1.1A). We obtained a similar trend when SC c-jun expression 
was examined in the motor branch of femoral nerves using immunostaining (Figure 





Figure 3.3.1.1: KU-596 decreases c-jun expression in young Cx32def mice. 
A) After treatment with CAP/KU-596 for one month, sciatic nerves were collected and prepared 
for immunoblot. KU-596 dose dependently decreased c-jun expression. B) c-Jun expression in the 
femoral nerve motor branch. KU-596 dose dependently decreased c-jun expression. C) 
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3.3.2. KU-596 treatment increased the motor function in young Cx32def mice 
Recent evidence revealed that axonopathy occurs earlier than the onset of 
demyelination in Cx32def mice (Vavlitou, Sargiannidou et al. 2010). Accordingly, 
another indication of axonal loss is that patients exhibit a reduced compound muscle 
action potential (CMAP) (Birouk et al 1998, Dubourg et al 2001). After one month of 
therapy, mice were anesthetized and nerve electrophysiology was assessed. Motor nerve 
conduction velocity (MNCV) reflects the integrity of the myelin while CMAP reflects 
axonal innervation of neuromuscular junction. KU-596 treatment improved both MNCV 




Figure 3.3.2.1: KU-596 improves motor function in young Cx32def mice. 
After treatment with CAP/KU-596 for one month, mice were subjected to electrophysiological 
assessments. KU-596 dose dependently increased both motor nerve conduction (MNCV) and 
compound muscle action potential (CMAP). *, p<0.05 vs. WT. #, p<0.05 vs. CAP. (WT, n=7, 
CAP, n=11, 0.3mg/kg KU-596, n=9, 1mg/kg KU-596, n=9, 3mg/kg KU-596, n=8). 
  
 77 
3.3.3. KU-596 treatment decreased c-jun expression in old Cx32def mice. 
The second stage of the CMT1X neuropathy is characterized by a profound 
elevation of c-jun, which takes place at around 6 months of age (Klein et al 2014). c-Jun 
drives SC demyelination (Parkinson et al 2008) and possibly regulates the expression of 
CCL2 (Wolter et al 2008) to exacerbate demyelination. To test whether KU-596 could 
attenuate c-jun expression and exhibit neuroprotection, we treated Cx32def mice daily for 
3 months with 3mg/kg KU-596. Consistent with previous literature (Klein et al 2014), 
Cx32def mice showed an increased level of c-jun in the motor branch of the femoral 
nerve compared to WT mice. 3-months of daily treatment with KU-596 decreased the 
level of c-jun as the percentage of c-jun+ profiles was reduced to half of the CAP treated 
mice (Figure 3.3.3.1). 
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Figure 3.3.3.1: KU-596 decreases c-jun expression in old Cx32def mice. 
A) After 3 months of treatment, femoral nerve motor branches of young Cx32def mice were fixed 
and stained with antibody against c-jun (red). B) Quantification of the percentage of c-jun+ 
nucleus per section. *, p<0.05 vs. WT. #, p<0.05 vs. CAP.   
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3.3.4. KU-596 treatment increased the motor function in old Cx32def mice. 
As increased levels of c-jun correlate with the decline of motor function, we 
tested whether KU-596 treatment improved measures of nerve physiology. First, we 
employed the grip strength test to measure the muscle strength of the mice. In our 3-
month dosing paradigm, we monitored the grip strength of the mice weekly. Compared 
with WT, Cx32def mice exhibit a progressive decline in muscle strength, as seen in 
previous literature (Groh et al 2010). This decrease in muscle strength is linked to the 
reduced CMAP seen in patients (Birouk et al 1998, Molin & Punga 2016). 3 weeks after 
treatment, the two groups began to differ. KU-596 treated animals improved their muscle 
strength, whereas CAP treated animals showed a progressive decline over time, as 
expected (Figure 3.3.4.1A).  
As a second measure, mice were placed on a Force Plate Actometer (FPA) to 
monitor changes in their locomotor activity. The FPA contains four force sensors each 
supporting a corner of the floor. When a mouse runs on the floor, the FPA automatically 
records the reactive forces and calculates the movement of a given mouse (Fowler et al 
2001). Mice were placed on the FPA for a 10 min session each week. The distance 
traveled within the 10min session was not different across groups. Figure 3.3.4.1C shows 
the maximum power (max power) of a mouse (normalized to % body weight) when 
running on the floor. KU-596 treatment improved the max power, indicating an 
improvement in force. In line with findings in the young mice, KU-596 treatment 
improved the MNCV and CMAP as well (Figure 3.3.4.1B and D). These data suggest 
that KU-596 treatment could improve the nerve function and muscle strength of Cx32def 
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mice, which could be translated to humans as muscle weakness, a major complaint from 
CMT1X patients.   
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Figure 3.3.4.1: KU-596 improves motor function of old Cx32def mice. 
KU-596 improves grip strength (A), MNCV (B), max power (C) and CMAP (D) in 9 
month-old Cx32def mice. Max power is measured as percent of body weight during a 
10min session on force plate actometer. *, p<0.05 vs. WT. #, p<0.05 vs. CAP.   
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3.3.5. KU-596 requires Hsp70 for efficacy. 
Our previous work has shown that the ability of KU-596 to protect against 
diabetic neuropathy is Hsp70-dependent (Ma et al 2015, Zhang et al 2018). We sought to 
explore whether Hsp70 is also required in preserving the nerve function in this model of 
CMT1X. We generated Cx32def x Hsp70 KO mice by crossing the Cx32def mice with 
Hsp70.1/70.3 knockout mice (Figure 3.3.5.1A). We included both young and old 
Cx32def x Hsp70 KO mice and followed the same experimental design as we did with 
the Cx32def mice that expressed Hsp70. Deletion of Hsp70 did not affect development of 
the neuropathy since MNCV, CMAP and grip strength were decreased to levels similar to 
that observed in the Cx323def mice. Thus, Hsp70 is not necessary for developing the 
neuromuscular deficits. However, in contrast to the Cx32def mice, KU-596 treatment 
showed no efficacy in improving the neuropathic phenotype in the Cx32def x Hsp70 KO 
mice. For example, c-jun levels were unchanged in the motor nerve femoral branches of 
young mice receiving 1 month of KU-596 treatment or old mice receiving 3 months of 
KU-596 treatment. In addition, KU-596 treatment failed to preserve motor function as 
mice receiving KU-596 treatment performed the same as CAP treated animals in the grip 
strength test and showed no improvements in MNCV and CMAP (Figure 3.3.5.1C, D, G-
I). Taken together, these data indicate that Hsp70 is required for drug efficacy, consistent 
with our previous findings in animal models of metabolic neuropathy (Li et al 2012a, Ma 
et al 2014, Zhang et al 2018). 
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Figure 3.3.5.1: KU-596 improves the motor deficit in an Hsp70 dependent manner. 
A) Genotype analysis of the Cx32def x Hsp70 KO mice (top). A, Hsp70 WT; B, Hsp70 KO; C, 
Cx32. Immunoblot analysis of sciatic nerve from three Cx32def and Cx32def x Hsp70 KO mice 
(bottom). B) Motor branches of femoral nerves of 4-month-old Cx32def x Hsp70KO mice were 
harvested after one-month of treatment. Cross sections were stained with antibody against c-jun 
(red). C) Quantification of the percentage of c-jun+ nuclei per section. D) KU-596 does not 
improve CMAP in the absence of Hsp70. E-F) Immunostaining of c-jun in cross sections of 
femoral nerve motor branch of 9-month-old Cx32def x Hsp70KO mice. Quantification is shown 
in F. G-I) KU-596 treatments did not improve the motor function of Cx32def x Hsp70KO mice. 
MNCV (G), CMAP (I) and muscle strength (H) were not changed following KU-596 treatment. 
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3.3.6. KU-596 may improve the neuropathy by decreasing macrophage 
recruitment 
Since CCL2 can be induced by c-jun and downregulation of CCL2 has been shown 
to be beneficial in Cx32def mice (Groh et al 2010), it is possible that the effects of KU-
596 may act through the c-jun-CCL2-macrophage axis. To test this hypothesis, we 
transfected 50B11 cells with a plasmid, which contains a CCL2 promoter driving 
expression of a Gaussia luciferase reporter. 
To determine if the drug had an effect on basal c-jun expression, the cells were 
treated for 14 hrs with 1 µM KU-596 while maintaining the cells in complete medium 
containing 10% serum.  Under these conditions, KU-596 had no effect on altering c-jun 
expression or luciferase activity, suggesting that the drug was not decreasing basal c-jun 
expression (Figure 3.3.6.1B). To determine if the drug might alter an increase in c-jun, 
transfected cells received vehicle or 1 µM KU-596 and were deprived of serum for 12h to 
induce quiescence. The cells were then re-stimulated with serum for 2h to induce c-jun. 
As expected, cells stimulated with 10% serum showed an increase in c-jun levels and 
luciferase activity. However, KU-596 treatment decreased the serum-induced increase in 
c-jun expression (Figure 3.3.6.1A) and luciferase activity. These data suggest that KU-
596 is blocking the serum-induced increase in c-jun levels but is not affecting basal levels 
present in the absence of serum deprivation.  
The above studies also supported that c-jun can activate the CCL2 promoter. To 
determine if KU-596 decreased CCL2 levels in vivo, extracts of sciatic nerve from mice 
treated for 3 months with KU-596 were used in a CCL2 ELISA. Due to the use of tissues 
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for other experiments, only three mice could be assessed. While CCL2 levels were 
increased in untreated Cx32def mice compared to WT animals, only two of three KU-596 
treated animals showed a robust decline in CCL2, which negated statistical significance 
(data not shown). CCL2 levels will be reassessed in an upcoming cohort of animals. 
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Figure 3.3.6.1: KU-596 decreases CCL2 luciferase activity. 
A) Luciferase activity of CCL2 in 50B11 cells. Cells were deprived of serum for 12h or remained 
in the complete medium as control and treated with the addition of 1µM KU-596. After 2h serum 
stimulation, media were collected for luciferase assay and cells lysates were used for western blot 
analysis. Serum induced c-jun expression and corresponding luciferase activity whereas KU-596 
treatment decreased both. *, p < 0.05 versus SF; # p< 0.05 vs DMSO. B) Luciferase activity of 
CCL2 in 50B11 cells without serum deprivation. Cells were treated with either Captisol or 1µM 
KU-596 overnight. Media were collected for luciferase activity assay and cell lysates western blot 
analysis. c-Jun expression and  luciferase activity remained regardless of treatment.   
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3.4. Discussion 
CMT1X is the second most prevalent form of CMT disease (Braathen 2012). 
Though not lethal, it severely affects the quality of life of CMT1X patients (Johnson et al 
2014). So far, treatment options are limited to surgeries, braces and pain management. 
Intrathecal gene delivery of Cx32 markedly improved the motor neuropathy in 
Cx32def mice (Kagiava et al 2016), yet there are many hurdles to translate such an 
approach to humans. Here we demonstrated that KU-596, a small molecule Hsp90 
inhibitor that is easily translatable to human patients, improved nerve function of 
Cx32def mice. 
The pathology of Cx32def mice presents in two stages, wherein a non-
demyelinating axonopathy occurs prior to a demyelinating axonopathy. A molecule of 
interest in both stages is the leucine zipper transcription factor c-jun. c-Jun is an AP-1 
transcription factor that plays important roles in demyelination. c-Jun inhibits myelin 
gene expression under normal conditions and is required for SC dedifferentiation 
(Parkinson et al 2008). During the first stage of the CMT1X axonopathy, c-jun 
expression is elevated likely due to the response to axonal injury. At this stage, c-jun 
switches on a repair program that downregulates myelin genes, increases the expression 
of trophic factors, initiates myelin clearance by activating SC autophagy and macrophage 
recruitment, and more importantly forms the Bungner’s band that guide axon 
regeneration (Jessen & Mirsky 2016). Glial cell-derived neurotrophic factor (GDNF) is 
found at elevated levels in c-jun positive SCs at this stage (Klein et al 2014), which is 
induced by c-jun as part of the repair program due to the presence of c-jun response 
elements in the GDNF gene promoter region (Arthur-Farraj et al 2012). If the c-jun 
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activated repair program is successful, the axons should be able to regenerate within a 
certain timeframe. However, an increase in GDNF is insufficient to halt disease 
progression and sustained high levels of c-jun lead to the gradual onset of SC 
demyelination. In addition, macrophages directly contribute to myelin degeneration in 
CMT1X (Martini & Willison 2016); their role is not secondary to myelin breakdown 
as seen in Wallerian degeneration (Martini et al 2013). It is possible that sustained high 
levels of c-jun lead to SC demyelination and add to the second wave of inflammatory 
assault, since CCL2 is driven by c-jun (Wolter et al 2008), which attracts macrophages 
and leads to the exacerbated demyelination (Figure 3.4.1). 	
We showed that the decrease of c-jun by KU-596 correlated with an improvement 
in nerve function in both young and old Cx32def mice in an Hsp70 dependent manner. 
However, the mechanism of decreased c-jun expression remains unknown. 
Mechanistically, Hsp70 inhibits the JNK pathway to protect neurons from apoptosis 
(Bienemann et al 2008, Lee et al 2005). However, phosphorylation of c-jun by JNK is 
neither necessary to drive demyelination (Parkinson et al 2008) nor to drive axon 
regeneration (Ruff et al 2012). In addition, we have previously shown that the decrease of 
c-jun in SC-neuronal co-cultures by KU-32 is due to an increased degradation but not a 
decreased production of c-jun (Li et al 2012a). In a transgenic mouse model where c-jun 
is selectively induced in SCs, pMAPK/MAPK level was not affected by KU-596 (Zhang 
et al 2018). Thus, we anticipate that the decrease of c-jun is likely due to an enhanced 
clearance rather than compromised production. In this regard, a protein of interest would 
be the F-box WD repeat domain-containing protein 7 (Fbw7). Fbw7 is an E3 ligase that 
mediates the degradation of c-jun after phosphorylation by GSK-3β at Thr239 and 
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Ser243(Wei et al 2005). In addition, Hsp70 could coimmunoprecipitate with Fbw7 
(unpublished data). These data suggest that KU-596 may decrease c-jun expression 
through Hsp70-Fbw7 mediated degradation. Further studies using mice that have a SC-
specific conditional deletion of Fbw7 crossed into the Cx32def background will help 
determine the role of Fbw7 in decreasing c-jun by KU-596. 
As c-jun not only drives SC dedifferentiation (Parkinson et al 2008) but also 
supports axon regeneration (Fontana et al 2012a, Ruff et al 2012), it is of vital importance 
to examine the physiological outcome of decreasing c-jun in Cx32def mice. We showed 
that decreased c-jun by KU-596 correlated with improved nerve function which could be 
linked to a decreased inflammatory response. KU-596 has been shown to downregulate 
the inflammatory transcriptome in a mouse model of DPN (Ma et al 2015). Another 
Hsp90 inhibitor, 17-AAG, improved neuron survival in a model of traumatic brain injury 
through down-regulating pro-inflammatory cytokines, such as TNF-α, IL-1β and IL-6 
(Gu et al 2016). In the Cx32def mice, mutant SCs send out a signal that induces 
endoneurial fibroblasts to secrete CSF-1, which activates the macrophage-mediated 
neurodegeneration. In the meantime, mutant SCs secrete CCL2 to recruit macrophages 
(Martini & Willison 2016). Since CCL2 could be induced by c-jun (Wolter et al 2008), 
we performed a luciferase assay to see if KU-596 could regulate CCL2 through c-jun 
using a luciferase reporter fused with CCL2 promoter. Serum induced the expression of 
c-jun and CCL2 in 50B11 cells whereas KU-596 treatment decreased the expression of c-
jun and CCL2 luciferase activity, indicating that KU-596 may regulate CCL2 expression 
through c-jun. This suggests that the improved nerve function could be due to decreased 
macrophage recruitment and activation through c-jun mediated downregulation of CCL2 
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by KU-596. Thus KU-596 may reduce axon damage through downregulating the c-jun-
CCL2-macrophage axis, leading to a decrease in axon damage and a further reduced 
expression of c-jun. This relationship will be more stringently addressed using Cx32def 
mice that have a SC-specific conditional deletion of c-jun.  
In the C3 mouse model of CMT1A, conditional deletion of SC-c-jun exacerbated 
the phenotypes of CMT1A and led to loss of myelin-competent neurons (Hantke et al 
2014). These data suggest that targeting c-jun may have unwanted side effects on 
neuronal survival. In contrast to genetic deletion, we showed that the decrease of c-jun by 
KU-596 correlates with an improvement in nerve function. The difference in the two 
experiments could be due to the level of c-jun. Instead of complete deletion, KU-596 
reduced the c-jun level to a lower state, which helps nerve regeneration without inducing 
demyelination (Figure 3.4.1). This is supported by recent work from Fazal et al., 2017 
where they examined graded c-jun expression on myelination (Fazal et al 2017). In mice 
that heterozygously overexpressed c-jun, developmental myelination was delayed but 
nerves were able to regenerate and functionally recover after injury. On the other hand, in 
mice that homozygously overexpressed c-jun, developmental myelination is inhibited. 
These data suggest that the expression level of c-jun is key to its function where moderate 
levels increase support for axon regeneration and high expression induces demyelination. 
Thus, KU-596 may reduce c-jun to moderate elevation level compared with normal 
condition to reduce axonopathy. Further studies using c-jun conditional knockout mice 
crossed with Cx32def mice will help determine whether c-jun is necessary for the effects 
of KU-596 as well as the role of c-jun in the disease progression. 	
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Another possible aspect that KU-596 could act on to attenuate axonopathy would 
be its documented ability to improve sensory neuron bioenergetics (Ma et al 2015), as 
ATP supply is critical for axonal regeneration (Han et al 2016, Zhou et al 2016). 
Innervation of the neuromuscular junction (MNJs) would be another factor that adds to 
the improvement. Cx32def mice have been shown to have an elevated level of denervated 
NMJs compared with WT at 12 months of age (Klein et al 2015). Injections of 
recombinant human Hsp70 arrested denervation and preserved large myelinated axons in 
a mouse model of amyotrophic lateral sclerosis (Gifondorwa et al 2012). Thus, it is 
possible that KU-596 improves the innervation of NMJs and the muscle grip strength 
through Hsp70. 
In summary, we provide evidence that KU-596 decreases c-jun expression and 
improves nerve function in both young and old Cx32def mice in an Hsp70 dependent 
manner. In Cx32def mice, an unknown assault leads to axon damage resulting in elevated 
c-jun expression. c-Jun upregulation leads to SC dedifferentiation as part of the repair 
program, which is insufficient to stop the disease progression. Sustained high levels of c-
jun lead to demyelination in the second stage. In the meantime, mutant SCs send an 
unknown signal to endoneurial fibroblasts which then secrete CSF-1 and activate 
macrophage-mediated degeneration. In addition, c-jun induces the transcription of CCL2, 
which leads to a second wave of demyelination. KU-596 may act on antagonizing c-jun-
CCL2-macrophage pathway and downregulating c-jun expression to a level that reduces 
axonopathy through an Hsp70 dependent manner, thus resulting in decreased c-jun level 
and improved nerve function. Improvement in innervation of NMJs and mitochondrial 
bioenergetics through Hsp70 mediated mechanisms may also add to the overall 
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improvement in function (Figure 3.4.1). Although further experiments are needed to pin 
down the mechanism, our data support the possibility of adding KU-596 as a therapeutic 





Figure 3.4.1: Proposed mechanism of action of KU-596. 
In Cx32def mice, an unknown assault leads to axon damage resulting in elevated c-jun 
expression. c-Jun upregulation leads to SC dedifferentiation as part of the repair program. The 
repair program is either unsuccessful or could not meet the rate of axon damage. Constant insult 
induced sustained high level of c-jun which may lead to the demyelination in the second stage. 
On the other hand, mutant SCs send an unknown signal to endoneurial fibroblasts which then 
secretes CSF-1 and activate macrophage-mediated degeneration. c-jun induces the transcription 
of CCL2 which may leads to a second wave of demyelination. KU-596 may act on antagonizing 
macrophage pathway and directly/indirectly downregulating c-jun expression to a level that could 
be well-tolerated through an Hsp70 dependent manner, thus resulting in decreased c-jun level and 
improved nerve function. Improvement in innervation of NMJs and mitochondrial bioenergetics 








Chapter 4. Outlooks 
Therapeutic strategies of demyelinating disorders currently remain limited. 
Understanding the molecular mechanism behind disease progression greatly facilitates 
finding the right targets for management. Recent studies revealed that c-jun is at the 
center of the SC demyelinating process. Upregulated c-jun expression leads to the 
inhibition of myelinating genes (Parkinson et al 2008) and such upregulation after nerve 
injury leads to SC demyelination and later support of axon regeneration (Fontana et al 
2012a, Ruff et al 2012). Results from our previously published work have shown that the 
Hsp90 inhibitor, KU-32, could attenuate the upregulation of c-jun induced by neuregulin 
in a SC-DRG co-culture model (Li et al 2012a). The effect is likely due to an increased 
degradation rather than compromised production, since the effects of KU-32 on 
downregulating c-jun were abolished when the proteasome was inhibited. Moreover, the 
protective effects of this compound rely on the presence of Hsp70 since cultures prepared 
from Hsp70KO mice failed to show improvement in the extent of myelination. The 
current work focused on investigating the in vivo effects of a next generation Hsp90 
inhibitor, KU-596, in the context of demyelinating neuropathies. Firstly, the results from 
the MPZ-RAF mice provided a proof of concept that attenuating the expression of c-jun 
by KU-596 could improve the motor function of these transgenic mice. Consistent with 
previous findings, KU-596 required Hsp70 for its efficacy. MPZ-RAF × Hsp70 KO mice 
treated with KU-596 did not show changes in c-jun expression level nor did they show 
any improvement in motor function compared with mice receiving the drug vehicle. 
Although this transgenic model proved useful to provide insight on the neuroprotective 
ability of KU-596, the model itself has some drawbacks. For example, the onset of the 
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neuropathy is very fast and it does not recapitulate the breadth of complex vascular, 
axonal, and SC interactions that contribute to the onset of neuromuscular deficits that 
contribute to many human neuropathies. Taken a step further, this strategy has been 
employed in a mouse model of an inherited neuropathy, CMT1X. The neuropathology of 
CMT1X has two stages, an initial axonopathy followed by a later stage of frank 
demyelination. KU-596 showed promising effects in downregulating c-jun expression 
and preserving nerve function in both young mice receiving 1 month of treatment and old 
mice receiving 3 months of treatment. In line with previous findings, the effects of KU-
596 appeared to be dependent on Hsp70 (Ma et al 2015, Zhang et al 2018). This study 
indicated that modulating molecular chaperones could be beneficial in the context of 
CMT1X, however the underlying mechanism remains to be uncovered.  
The mechanism of how c-jun is cleared is unknown. It is possible that KU-596 
functions post-transcriptionally to regulate c-jun expression. c-Jun is first phosphorylated 
by GSK-3β at Thr239 and Ser243 and then transported to the proteasome for degradation by 
the E3 ligase Fbw7 (Welcker et al 2004). As Fbw7 can coimmunoprecipitate with Hsp70 
(data not shown), it is possible that KU-596 decreases c-jun expression through an 
Hsp70-Fbw7 interaction. To investigate the role of Fbw7 on the degradation of c-jun, our 
lab has generated mice with SC-specific deletion of Fbw7. Fbw7 has been found to 
inhibit myelin gene expression in oligodendrocytes through inhibiting the mTOR 
pathway (Kearns et al 2015). As deletion of Fbw7 is associated with the hypomyelination 
phenotype, the first question we would like to answer is whether this strain would present 
an exacerbated phenotype when crossed with the Cx32 def mice. The second question we 
would like to answer is whether the deletion of this protein influences the level of c-jun 
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as the disease progress. If Fbw7 is important for c-jun clearance, then the onset of the 
neuropathy may be faster and the neuromuscular phenotype exacerbated. The third 
question we would like to answer is whether this protein is critical for KU-596 to 
function. We might anticipate that the drug would lose efficacy if Fbw7 is critical for 
clearing c-jun. 
Another aspect we would like to focus on is the necessity of c-jun for the effects 
of KU-596. The findings in this dissertation provide a correlation between decreased c-
jun function and improved nerve function. However, no causal relationship could be 
derived based on this study design. It is possible that the altered expression level of c-jun 
is secondary to other changes following KU-596 treatment. Inflammation plays a key role 
in the progression of CMT1X, as Cx32def mice deficient in T- and B- lymphocytes 
showed a mitigated phenotype (Kobsar et al 2003) and heterozygous deletion of CCL2 
alleviated the symptoms of CMT1X (Groh et al 2010). Several lines of data suggest that 
induction of Hsp70 could reduce inflammation and provide neuroprotection. Induction of 
Hsp70 by the Hsp90 inhibitor, 17-AAG, has been shown to promote optic neuron 
survival after injury (Kwong et al 2015). The effect of 17-AAG could likely be due to an 
anti-inflammatory action since the protection of 17-AAG on motor neurons after 
traumatic brain injury is associated with a decrease in TNF-α, IL-1β and IL-6 (Gu et al 
2016). Hsp70 has also been shown to suppress NF-κB signaling and the production of 
inflammatory cytokines (Chen et al 2006). In experimental stroke, overexpressing Hsp70 
inhibited microglia activation (Yenari et al 2005). Moreover, KU-596 decreased the 
inflammatory transcriptome upregulated by DPN (Ma et al 2015). It is possible that 
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through down-regulating inflammation, KU-596 protected neurons of Cx32def mice 
while c-jun level was decreased as a result of attenuated axonal damage.  
To more rigorously investigate the role of c-jun in drug efficacy, we have 
generated another mouse model with a SC-specific deletion of c-jun crossed into the 
Cx32def background. This model would not only give us an idea as how the effects of 
KU-596 and c-jun levels are related, but also how the c-jun protein itself contributes to 
the disease. However, there are concerns about the phenotype of c-junf/f mice. Recent 
evidence has suggested that genetic deletion of c-jun in a mouse model of CMT1A 
exacerbated the phenotype and led to loss of sensory neurons (Hantke et al 2014), 
indicating c-jun may have a protective role in addition to inducing demyelination. It 
seems that c-junf/f × Cx32def mice may have an exacerbated phenotype compared with 
Cx32def mice and the symptoms may occur at an earlier stage. If these mice fail to show 
improvement after KU-596 therapy, then the protective effects of KU-596 are c-jun 
dependent. If these mice are able to response to KU-596 therapy, the protective effects of 
KU-596 may be c-jun independent; the reduced c-jun expression seen in the Cx32def 
mice is secondary to other protective mechanisms.  
Mitochondrial function could be another interesting area to explore. Recent 
evidence suggests a role of mitochondria in axon degeneration. The opening of 
mitochondrial permeability transition pore leads to axonal degeneration induced by 
mechanical or toxic stimuli (Barrientos et al 2011). Mitochondrial depolarization could 
induce axon degeneration independent of apoptosis (Gerdts et al 2013). Depolarized 
mitochondria are associated with the release of reactive oxygen species (ROS) and 
reduced energy supply (O'Donnell et al 2013). KU-596 has been demonstrated to 
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improve sensory neuron bioenergetics and reduce ROS production in models of diabetic 
peripheral neuropathy (Ma et al 2014, Ma et al 2015). Therefore, it is possible that KU-
596 improved mitochondrial function that contributes to aspects of the neuromuscular 
improvement. Further studies looking at the mitochondrial function in young and old 
mice would help elucidate the role of mitochondrial dysfunction in the progression of the 
disease and whether KU-596 would exhibit protective effects.  
Innervation of the neuromuscular junction (NMJs) would be another exciting area 
to look at, as CMT1X is a neuromuscular disease to start with. Cx32def mice have been 
shown to have an elevated level of denervated NMJs compared to WT mice at 12 months 
of age (Klein et al 2015). Injections of recombinant human Hsp70 arrested denervation 
and preserved large myelinated axons in a mouse model of amyotrophic lateral sclerosis 
(Gifondorwa et al 2012). Thus, it is possible that KU-596 could act on NMJs and 
improved the muscle grip strength through Hsp70. 
In summary, this dissertation provides further evidence that modulating molecular 
chaperones could be beneficial in managing demyelinating neuropathies. Although 
further studies are needed, it is possible that KU5-96 could improve nerve function of 
Cx32def mice through multiple mechanisms, including decreasing c-jun expression and 
inflammatory pathways. Since KU-596 is entering Phase 2 clinical trials, novologue 
therapy could be a promising translatable approach towards human demyelinating 
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